



C12 N 15/31

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> :	A2	(11) International Publication Number: WO 88/05823
C12N 15/00, A61K 39/04 G01N 33/569		(43) International Publication Date: 11 August 1988 (11.08.88)
(21) International Application Number: PCT/US88/00281		(74) Agents: GRANAHAN, Patricia et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).
(22) International Filing Date: 1 February 1988 (01.02.88)		
(31) Priority Application Number: 010,007		(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).
(32) Priority Date: 2 February 1987 (02.02.87)		
(33) Priority Country: US		
Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH [US/US]; Nine Cambridge Center, Cambridge, MA 02142 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>
Inventors: HUSSON, Robert, N. ; 60 Parkman Street, Brookline, MA 02146 (US). YOUNG, Richard, A. ; 11 Sussex Road, Winchester, MA 01890 (US). SHINNICK, Thomas, M. ; 1434 Rainier Falls Drive, Atlanta, GA 30329 (US).		

(54) Title: MYCOBACTERIUM TUBERCULOSIS GENES ENCODING PROTEIN ANTIGENS

## (57) Abstract

*Mycobacterium tuberculosis* genes encoding five immunologically relevant proteins have been isolated by systematically screening a lambda gt11 recombinant DNA expression library with a collection of murine monoclonal antibodies directed against protein antigens of this pathogen. One of the *M. tuberculosis* antigens, a 65kD protein, has been shown to have determinants common to *M. tuberculosis* and *M. leprae*. In addition, genes encoding proteins of other mycobacteria (*M. africanum*, *M. smegmatis*, *M. bovis* BCG and *M. avium*) have been isolated. Isolation and characterization of genes encoding major protein antigens of *M. tuberculosis* make it possible to develop reagents useful in the diagnosis, prevention and treatment of tuberculosis. They can be used, for example, in the development of skin tests, serodiagnostic tests and vaccines specific for tuberculosis.

AN3

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria  
AU Australia  
BB Barbados  
BE Belgium  
BG Bulgaria  
BJ Benin  
BR Brazil  
CF Central African Republic  
CG Congo  
CH Switzerland  
CM Cameroon  
DE Germany, Federal Republic of  
DK Denmark  
FI Finland

FR France  
GA Gabon  
GB United Kingdom  
HU Hungary  
IT Italy  
JP Japan  
KP Democratic People's Republic of Korea  
KR Republic of Korea  
LI Liechtenstein  
LK Sri Lanka  
LU Luxembourg  
MC Monaco  
MG Madagascar

ML Mali  
MR Mauritania  
MW Malawi  
NL Netherlands  
NO Norway  
RO Romania  
SD Sudan  
SE Sweden  
SN Senegal  
SU Soviet Union  
TD Chad  
TG Togo  
US United States of America

-1-

MYCOBACTERIUM TUBERCULOSIS GENES AND  
ENCODING PROTEIN ANTIGENS

Description

Background

05        Tuberculosis was the major cause of infectious mortality in Europe and the United States in the 19th and early 20th centuries. Dubos, R. and J. Dubos, The White Plague: Tuberculosis, Man and Society, Little Brown & Co., Boston, MA, (1952).  
10        Today, it remains a significant global health problem.

For example, in the United States there are over 20,000 new cases of tuberculosis diagnosed annually. In addition, the steadily declining incidence of tuberculosis evident in preceding years appears to have changed course, reaching a plateau in 1985 and showing an increase in the first half of 1986. Centers for Disease Control, Morbidity/Mortality, Weekly Report, 34:774 (1986); and Centers for Disease Control, Morbidity/Mortality, Weekly Report, 35:774 (1986).

Worldwide, tuberculosis remains widespread and constitutes a health problem of major proportions, particularly in developing countries. The World Health Organization estimates that there are ten million new cases of active tuberculosis per year and an annual mortality of approximately three

-2-

million. Joint International Union Against Tuberculosis and World Health Organization Study Group, Tubercle, 63:157-169 (1982).

05      Tuberculosis is caused by Mycobacterium (M.) tuberculosis or Mycobacterium (M.) bovis, which are the 'tubercle bacilli' of the family Mycobacteriaceae. M. bovis is a species which causes tuberculosis in cattle and is transmissible to humans and other animals, in whom it causes tuberculosis. At 10 present, nearly all tuberculosis is caused by respiratory infection with M. tuberculosis. Infection may be asymptomatic in some, but in other individuals, it produces pulmonary lesions which lead to severe debilitation or death. Resistance to 15 tuberculosis is provided by cell-mediated immune mechanisms.

20      Mycobacteria are aerobic, acid-fast, non-spore-forming, non-motile bacilli with high lipid contents and slow generation times. M. leprae is the etiologic agent of leprosy and, among the other mycobacteria, the only major pathogen. Bloom, B.R. and T. Godal, Review of Infectious Diseases, 5:765-780 (1983). However, other mycobacterial species are capable of causing disease. Wallace, R.J. et.al., 25 Review of Infectious Diseases, 5:657-679 (1984). M. avium, for example, causes tuberculosis in fowl and in other birds. Members of the M. Avium-intracellularae complex have become important pathogens among individuals with acquired immunodeficiency syndrome (AIDS). Certain groups of 30

-3-

individuals with AIDS have a markedly increased incidence of tuberculosis-as well. Pitchenik, A.E. et. al., Annals of Internal Medicine, 101:641-645 (1984).

05 Diagnostic and immunoprophylactic measures for mycobacterial diseases have changed little in the past half century. Tuberculin, developed by Koch as a cure for tuberculosis in the late 1800s, is an M. tuberculosis filtrate of complex and poorly-defined composition. It is used as a skin test antigen to detect prior exposure to the bacillus. Enrichment of the protein fraction of this material in the 1930's produced the purified protein derivative (PPD) which is still used to diagnose exposure to 10 tuberculosis. Seibert, F.M. et.al., American Review of Tuberculosis, 30(Suppl.):705-778 (1934). Its usefulness is limited, however, by its lack of specificity and its inability to distinguish active disease from prior sensitization by contact with M. tuberculosis or cross-sensitization to other mycobacteria. Young, R.A. and R.W. Davis, Proceedings of the National Academy of Sciences, USA, 80:194-20

15 1198. (1983).

20 Bacille Calmette Guerin (BCG), an avirulent strain of M. bovis, has been used widely as a live vaccine against tuberculosis for over 50 years. 25 Calmette, A., C. et.al., Bulletin of the Academy of

-4-

Medicine Paris, 91:787-796 (1924). During that time, numerous studies have shown that BCG has protective efficacy against tuberculosis. These studies are reviewed by F. Luelmo in American Review of Respiratory Diseases, 125(pt. 2):70-72 (1982). However, more recently, a major trial of BCG in India indicated that such a vaccine was not protective against tuberculosis in this setting. World Health Organization WHO Technical Report Series, 651 (1980). Presently available approaches to diagnosing, preventing and treating tuberculosis are limited in their effectiveness and must be improved if a solution is to be found for the important public health problem tuberculosis represents worldwide.

#### Summary of the Invention

The present invention is based on the isolation of genes encoding immunogenic protein antigens of the tubercle bacillus Mycobacterium tuberculosis (M. tuberculosis). Genes encoding such protein antigens have been isolated from a recombinant DNA expression library of M. tuberculosis DNA. Genes encoding proteins of four additional mycobacteria have also been isolated and restriction maps produced.

In particular, genes encoding five immunodominant protein antigens of the tuberculosis bacillus (i.e., those M. tuberculosis proteins of molecular weight 12,000 daltons (12kD), 14kD, 19kD, 65kD and 71kD have been isolated by probing a lambda gt11 expression library of M. tuberculosis DNA with

-5-

monoclonal antibodies directed against M.  
tuberculosis-specific antigens.

Recombinant DNA clones producing the specific  
antigenic determinants recognized by the monoclonal  
05 antigens were also isolated in this manner. DNA  
from such recombinant lambda gt11 clones was mapped  
with restriction endonucleases; the restriction maps  
for genes encoding the five immunodominant protein  
antigens (i.e., genes encoding the 12kD, 14kD, 19kD,  
10 65kD and 71kD proteins) were deduced. The nucleo-  
tide sequence of three of the genes have been deter-  
mined and, in each case, the amino acid sequence of  
the encoded protein has been deduced.

Brief Description of the Drawings

15 Figure 1 shows restriction maps of M. tuberculosis DNA. Recombinant DNA clones isolated with  
monoclonal antibodies directed against the 12kD,  
14kD, 19kD, 65kD and 71kD protein antigens were  
mapped with restriction endonucleases. The insert  
20 DNA endpoints are designated left (L) or right (R)  
in relation to lac Z transcripts which traverse the  
insert from right to left. Restriction sites are  
represented as follows: A, Sal I; B, BamHI; E,  
EcoRI; G, BglIII; K, KpnI; P, PvuI; S, SacI; X, XhoI.

25 Figure 2 shows arrays of antigens from M.  
tuberculosis recombinant DNA clones probed with  
rabbit hyperimmune serum. The code of the recombi-  
nant DNA clones shown on the numbers filter is: 1,  
Y3275; 2, Y3274; 3, Y3279; 4, Y3277; 5, Y3247; 6,  
30 Y3272; 7, Y3150; 8, Y3254; 9, Y3147; 10, Y3163; 11,

-6-

Y3179; 12, Y3191; 13, Y3252; 14, Y3178; 15, Y3180; 16, Y3143; 17, lambda gt11. Clones 1, 5, 6, 7, 9 and 16 are M. tuberculosis recombinants described in the following section. Clones 10, 11, 14 and 15 are 05 M. leprae recombinants expressing epitopes of the 18kD, 28kD, 36kD and 65kD antigens, respectively. Clones 2, 3, 4, 8, 12, 13 are uncharacterized recombinants from the lambda gt11 M. tuberculosis and M. leprae libraries. Clone 17 is a non-recombinant lambda gt11 control.

Figure 3 shows arrays of recombinant mycobacterial antigens probed with monoclonal antibodies to assess the extent of cross-reactivity between recombinant protein antigen of M. tuberculosis and 15 of M. leprae. The array of clones is identical to that shown in Figure 2. Antibody probes and the antigen sizes recognized are: 1, IT-11 (71kD); 2, IT-31 (65kD); 3, IT-16 (19kD); 4, IT-1 (14kD); 5, IT-3 (12kD).

20 Figure 4 shows restriction maps of DNA encoding four proteins (71kD, 65kD, 19kD and 14kD) of M. tuberculosis and four proteins (71kD, 65kD, 19kD and 14kD) of M. bovis BCG. Restriction sites are represented as follows: A, AatII; B, BamH1; C, 25 BcII; D, DraIII; E=EcoRI; G, BglIII; H, HinfI; K, KpnI; P, PstI; S, SalI; V, PvuI and X, XhoI.

Figure 5 is a comparison of restriction maps of the gene encoding the 65kD protein of 6 mycobacteria ( M. leprae, M. tuberculosis, M. africanum, M. bovis 30 BCG, M. smegmatis, M. avium). Restriction sites are

-7-

as follows: B, BamH<sub>1</sub>; K, KpnI; N, SacI; P, PvuI; S, SalI; X, XbaI.

Figure 6 is the nucleotide sequence of the region containing the M. tuberculosis 19kD gene.  
05 The deduced amino acid sequence of the encoded protein is also represented (protein start position, nucleotide 1110; protein stop position, nucleotide 1586).

Figure 7 is the nucleotide sequence of the 10 region containing the M. tuberculosis 71kD gene and the deduced amino acid sequence of the encoded protein.

Figure 8 is the nucleotide sequence of the region containing the M. tuberculosis 65kD gene.  
15 The deduced amino acid sequences of the two long open reading frames are presented in one letter code over (540) or under (517) the appropriate triplets.

#### Detailed Description of the Invention

The invention described herein is based on the 20 isolation of genes encoding immunogenic protein antigens of the bacillus M. tuberculosis, which is the major etiologic agent of tuberculosis. In particular, it is based on the isolation, using monoclonal antibodies directed against M.  
25 tuberculosis-specific antigens, of genes encoding five immunogenic protein antigens of the tuberculosis bacillus; these five antigens are immunodominant. Immunogenic antigens are those which elicit a response from the immune system.  
30 Immunodominant protein antigens are immunogenic

-8-

antigens against which the immune system directs a significant portion of its response. Genes encoding M. tuberculosis antigens of molecular weight 12,000 daltons (12kD), 14kD, 19kD, 65kD and 71kD were  
05 isolated in this manner.

Isolation and characterization of major protein antigens of M. tuberculosis, as described herein, make it possible to develop more effective tools for the prevention, diagnosis, and treatment of tuberculosis.  
10 Identification and isolation of genes encoding five immunodominant M. tuberculosis protein antigens, as well as of the five protein antigens, are described below; uses of the genes and encoded products are also described.

15 M. bovis BCG DNA clones were also isolated for the genes encoding the 71kD, 65kD, 19kD and 14kD proteins. In order to compare M. bovis BCG and M. tuberculosis genes encoding proteins of similar molecular weight, restriction endonuclease maps were  
20 determined for DNA segments containing each of the genes. Restriction maps for each of these genes is represented in Figure 4.

In addition, DNA clones were isolated for the genes encoding the 65kD protein from M. africanum,  
25 M. smegmatis and M. avium. Restriction endonuclease maps were determined for DNA segments containing each of these genes. The restriction maps for these genes, as well as for the genes encoding the 65kD protein of M. tuberculosis, M. bovis BCG and M. leprae, are represented in Figure 5.

-9-

I. Construction of a recombinant expression library of M. tuberculosis DNA

A recombinant DNA expression library of M. tuberculosis DNA was constructed using lambda gt11. 05 The library was constructed with M. tuberculosis genomic DNA fragments in such a way that all protein-coding sequences would be represented and expressed. Young, R.A., B.R. Bloom, C.M. Grosskinsky, J. Ivanyi, D. Thomas and R.W. Davis, 10 Proceedings of the National Academy of Sciences, USA, 82:2583-2587 (1985).

Lambda gt11 is a bacteriophage vector which is capable of driving the expression of foreign insert DNA with E. coli transcription and translation 15 signals. Lambda gt11 expresses the insert DNA as a fusion protein connected to the E. coli Beta-galactosidase polypeptide. This approach ensures that the foreign DNA sequence will be efficiently transcribed and translated in E. coli. This approach is also useful in addressing the problem of the highly unstable nature of most foreign proteins; fusion proteins are often more resistant to proteolytic degradation than is the foreign polypeptide alone. Lambda gt11 and the E. coli strain used 20 (Y1090) have been described previously. Young, R.A. et al., Proceedings of the National Academy of Sciences, USA, 80:1194-1198 (1983); Young, R.A. and R.W. Davis, Science, 222:778-782 (1983). The teachings of these publications are incorporated 25 herein by reference. The library constructed in 30 this manner has a titer of  $1 \times 10^{10}$  pfu/ml. and

-10-

contains approximately 40% recombinants with an average insert size of 4kB.

II. Screening of the lambda gt11 M. tuberculosis library with antibody probes

05 Murine monoclonal antibodies to protein antigens of M. tuberculosis were used individually to probe the M. tuberculosis recombinant DNA library. This work is described below and with specific reference to the 65kD antigen in the Exemplification. The antibodies used as probes and the sizes of the antigens to which they bind are shown below.

	<u>M. tuberculosis</u>	
	<u>Antibody</u>	<u>Antigen</u>
	IT-3	12kD
15	IT-20	14kD
	IT-19	19kD
	IT-27	19kD
	IT-17	23kD
	IT-29	23kD
20	IT-15	38kD
	IT-21	38kD
	IT-23	38kD
	IT-13	65kD
	IT-31	65kD
25	IT-33	65kD
	IT-11	71kD

Engers, H.D. et al., Infectious Immunology,  
51:718-720 (1986).

-11-

All monoclonal antibodies were used at approximately 1:200 to 1:300 dilution in 50mM Tris-HCl pH8/150 mM NaCl/.05% Tween 20.

Screening of the lambda gt11 recombinant DNA library was performed as described by Young et al. in Proceedings of the National Academy of Sciences, USA, 82:2583-2587 (1985), the teachings of which are incorporated herein by reference. One modification was made in the method described by Young and co-workers: 1% bovine serum albumin was used in place of 20% fetal calf serum to decrease background.

Briefly, cloned lambda gt11 recombinants were arrayed on lawns of E. coli Y1090. The phage were grown, antigen expression was induced and the antigens were blotted and probed with serum. Detection of signal-producing plaques was performed with a biotinylated secondary antibody system (Vectastain, Vector Laboratories, Burlingame, CA) or with an alkaline phosphatase conjugated secondary antibody system (Protoblot, Promega Biotec, Madison, WI), both used according to manufacturer's instructions. Signal-producing clones were isolated using antibodies directed against protein antigens of molecular weight 12kD, 14kD, 19kD and 65kD and 71kD. In each case, similar numbers of clones were isolated in screens of approximately  $10^5$  recombinant plaques. DNA clones encoding the 23kD and 38kD antigens could not be detected with these antibodies, possibly because the native epitope is modified or topographically complex, or because the

-12-

antigen-antibody interaction is too weak to be recognized by current detection methods.

III. Probing of Arrays of lambda gt11 DNA Clones with Antibody Probes

- 05        0.2 ml of a saturated culture of Y1090 was added to 2.5 ml of molten LB soft agar, poured onto 100 mm plates containing 1.5% LB agar and allowed to harden at room temperature for 10 min. 100 ul of phage plate stock containing approximately  $10^{11}$  pfu/ml of the lambda gt11 DNA clones of interest were placed into alternate wells of 96-well tissue culture plates. A multi-pronged transfer device was placed briefly in the wells containing phage and then touched lightly to the surface of the plate onto which the soft agar had been poured. The plates were then incubated at 42°C for approximately 3 hours, at which point clear plaques approximately 5mm in diameter were visible. The plates were then overlayed with nitrocellulose filters saturated with 10mM isopropylthiogalactoside (IPTG) and incubated at 37°C for 3.5 hours. Subsequent processing of filters for detection of antigen was identical to the procedures described for screening of lambda gt11 library with antibody probes.
- 20        25        Immunoscreening of the lambda gt11 library to isolate clones reactive with monoclonal antibodies specific for the 65kD antigen is described in the Exemplification.

-13-

#### IV. Recombinant DNA Manipulation

DNA from recombinant lambda gt11 clones was isolated and mapped with restriction endonucleases by standard techniques. Davis, R.W. et al.,  
05 Advanced Bacterial Genetics: A Manual for Genetic Engineering, Cold Spring Harbor (1980).

Figure 1 shows the genomic DNA restriction map deduced for each of the genes encoding the five M. tuberculosis antigens and illustrates how each of  
10 the cloned DNAs aligns with that map. All clones isolated with monoclonal antibodies directed against any single antigen align with a single genomic DNA segment. This indicates that all clones were isolated because they express the protein of interest rather than an unrelated polypeptide containing  
15 a similar or identical epitope. In addition, this result suggests that each antigen is the product of a single gene.

The orientation of each DNA insert in the recombinant clones was determined by restriction analysis. Only among the clones for the 65kD antigen were the inserts found in both possible orientations relative to the direction of lac Z transcription in lambda gt11. This suggests that  
20 this protein can be expressed in E. coli from signals independent of those provided by lac Z. Similar results have been obtained for recombinant DNA clones encoding the 65kD antigens of M. bovis and M. leprae. Thole, J.E.R. et al., Infectious Immunology, 50:800-806 (1985); Young, R.A. et al.,  
25 Nature, 316:450-452 (1985).

-14-

The nucleotide sequences of three regions of the M. tuberculosis DNA were determined: 1) the region containing the M. tuberculosis 19kD gene; 2) the region containing the M. tuberculosis 71kD gene; 05 and 3) the region containing the 65kD gene. The three sequences are represented in Figures 6-8. Sequences were determined using standard techniques, which are described in the Exemplification.

V. Filter hybridization of Insert DNA

10 Arrays of lambda gt11 clones were created as described above and incubated at 42° for 5 hours. The plates were then overlayed with nitrocellulose filters and placed at 4°C for 1 hour. Probe DNA was labelled with <sup>32</sup>P by nick translation. Filter 15 hybridization was performed as described by Davis et al. in Advanced Bacterial Genetics: A Manual for Genetic Engineering, Cold Spring Harbor (1980), the teachings of which are incorporated herein by reference. Hybridization conditions were as follows: 50% 20 v/v formamide, 5x SSPE (1x SSPE is 0.18M NaCl, 10mM Na<sub>1.5</sub>H<sub>1.5</sub>PO<sub>4</sub>, 1mM Na<sub>2</sub>EDTA, pH 7.0), 1x Denhardt's solution (0.02% w/v Ficoll, 0.02% w/v polyvinyl-pyrrolidone, 0.02% w/v bovine serum albumin), 0.3% NaDodSO<sub>4</sub> at 42°C for approximately 16 hours, followed by washing in 2x SSPE, 0.2% NaDodSO<sub>4</sub> at 45°C. 25

VI. Recombinant Antigens Recognized by Rabbit Serum

The response of a second animal to an antigen preparation of M. tuberculosis was assessed by

-15-

examining the reactivity of rabbit anti-M. tuberculosis hyperimmune sera with recombinant antigens. Cloned lambda gt11 recombinants were arrayed on lawns of E. coli and probed with the rabbit hyper-immune serum. Anti-M. tuberculosis hyperimmune serum, produced by repeated immunization of rabbits with M. tuberculosis H37Rv culture filtrate, was provided by J. Bennedsen (Statens Serum Institut, Copenhagen, Denmark). These sera were used at 1:100 dilution.

These sera produced positive signals with lambda gt11 clones encoding each of the five M. tuberculosis epitopes which had been isolated with murine monoclonal antibodies (Figure 2). Particularly strong signals were observed with the 65kD and 71kD antigens (Figure 2). These results demonstrate that mice and rabbits can mount an antibody response to the same protein antigens of M. tuberculosis.

Clones for the five M. tuberculosis antigens were detected at similar frequencies in the lambda gt11 recombinant DNA library. Thus, the number and type of antigen-producing clones isolated with polyclonal serum antibodies should reflect the relative titer and diversity of the individual antibodies in this serum.

To determine whether any of the 5 M. tuberculosis antigens are relatively immunodominant in the rabbit humoral immune response to M. tuberculosis, the M. tuberculosis lambda gt11 recombinant DNA library was screened with the rabbit serum. Forty signal-producing clones were isolated, arrayed on

-16-

lawns of E. coli Y1090 and probed with monoclonal antibodies directed against each of the 5 recombinant M. tuberculosis protein antigens. Remarkably, 17 of the 40 clones (43%) reacted strongly with at least one of the four anti-65kD monoclonal antibodies tested. An additional six clones (15%) reacted strongly with the anti-17kD monoclonal antibody (IT-11). This indicates that a large proportion of the anti-M. tuberculosis antibody present in the rabbit serum was directed against the 65kD antigen of M. tuberculosis and suggests that it is a dominant antigen for the rabbit humoral immune response. Seventeen of the clones did not react with any of the monoclonal antibodies tested, suggesting that the rabbit sera may identify M. tuberculosis proteins not recognized by the murine antibodies.

#### VII. Antigenic Relatedness of M. tuberculosis and M. leprae Proteins

There is evidence that M. tuberculosis and M. leprae share immunologically important antigens. To assess this further, an investigation of the exact nature of the immunological relatedness among recombinant protein antigens of M. tuberculosis and M. leprae was conducted.

For each of five M. tuberculosis and four M. leprae protein antigens, a single recombinant DNA clone containing most or all of the gene of interest was used to express antigen in the following manner. The recombinant phage clones were arrayed on a lawn

-17-

of E. coli Y1090, which was then grown and induced for antigen expression.

Antigen immobilized on nitrocellulose filters was then probed with 26 individual anti-M. tuberculosis and M. leprae monoclonal antibodies. Figure 3 shows the array of DNA clones used and the results obtained with the anti-M. tuberculosis antibodies IT-1, IT-3, IT-11, IT-16, and IT-31, which recognized proteins of 14kD, 12kD, 71kD, 19kD and 65kD respectively. Table 1 details the full results of these cross-screening experiments, showing the reactivity of antigen expressed from individual recombinant DNA clones with each of the individual monoclonal antibodies. Clones were scored as positive only if the signal produced was clearly greater than the background signal produced by the non-recombinant lambda gt11 clone included in each array.

-18-

**TABLE 1**  
**Reactivity of Monoclonal Antibodies with**  
**Recombinant Protein Antigens**

-19-

Several conclusions can be drawn from the results shown in Table 1. Among the 11 monoclonal antibodies that recognize a 65kD antigen, 7 react with the 65kD protein from both mycobacteria (IT-31, 05 C1.1, IIH9 (identical to IT-33), IIC8, T2.3, Y1-2, SA2.D7C), one antibody reacts only with the M. tuberculosis 65kD protein (IT-13), and two antibodies react only with the M. leprae 65kD protein (IIIE9 and IIIC8). One antibody, ML30A, 10 cross-reacts with an antigen in E. coli and could not specifically identify antigen-producing clones. These results indicate that the 65kD protein antigens of M. tuberculosis and M. leprae are homologues and share a number of epitopes. In 15 addition to these shared epitopes, however, both 65kD antigens have epitopes that are specific for one species relative to the other.

No cross-reactivity was observed between other antigens of these two mycobacterial species. 20 Because monoclonal antibodies recognize a single epitope and because only one or a few antibodies were available for each antigen, it is not clear whether the 65kD proteins are the only homologous protein antigens of M. tuberculosis and M. leprae. 25 Among the antigens for which lambda gt11 clones have been isolated, the 18kD antigen of M. leprae and the 19kD antigen of M. tuberculosis are of similar size. To determine whether these two antigens are related, the homology of the DNA sequences that encode these 30 antigens was examined. At conditions of moderate stringency, no hybridization was observed between

-20-

- the insert DNA and Y3147 (an M. tuberculosis 19kD clone) and Y3179 (an M. leprae 18kD clone). This indicates no significant homology between the DNA sequences of the insert DNAs of these two clones.
- 05 This result suggests that the M. tuberculosis 19kD and the M. leprae 18kD proteins are unlikely to be homologous.

As a result of the work described, recombinant DNA clones encoding five major protein antigens of M. tuberculosis were isolated through the use of an extensive collection of well-characterized murine monoclonal antibodies. These five proteins were also found to be major antigens in the rabbit humoral immune response to M. tuberculosis. One of 15 these antigens, the 65kD protein, is shared with another other mycobacterial pathogen M. leprae.

Several lines of evidence indicate that the 65kD antigen is among the most immunodominant of the protein antigens of M. tuberculosis. Eleven of the 20 25 different M. tuberculosis and M. leprae monoclonal antibodies examined in this study recognized the 65kD recombinant antigen from one or both mycobacteria. In addition, almost half of the recombinant DNA clones isolated with rabbit poly- 25 clonal anti-M. tuberculosis sera express the 65kD antigen, reflecting the predominance of antibody to this antigen in these sera.

Considerable evidence indicates that the 65kD antigen plays an important role in the human response to tuberculosis. Antibodies directed against 30 this protein can be detected in the serum of

-21-

patients with tuberculosis. The 65kD antigen is present in purified protein derivatives (PPD's) of M. tuberculosis, M. bovis, and other mycobacteria. Thole, J.E.R. et al., Infection Immunity, 50:800-806 (1985). Finally, helper T cell clones reactive with recombinant 65kD antigen have been isolated from patients with tuberculosis, indicating that this antigen is involved in the cell-mediated as well as the humoral immune response to tuberculosis.

Among the major antigens of the leprosy bacillus, the 65kD antigen appears to elicit antibody and T cell responses similar to those observed for the M. tuberculosis antigen. Both serum antibodies and T cells directed against the 65kD M. leprae antigen have been observed in patients with leprosy. Britton, W.J. et al., Journal of Immunology, 135:4171-4177 (1985); Mustafa, A.S. et al., Nature, 319:63-66 (1986). In addition, T cell clones from leprosy patients have been found to respond to recombinant 65kD protein of M. bovis, as well as to PPD's from both M. bovis BCG and M. leprae. Emmrich, F. et al., Journal of Experimental Medicine, 163:1024-1029 (1986); Shankar, P. et al., Journal of Immunology, 136:4255-4263 (1986). It is interesting to note that in vaccine trials in Asia and Africa, BCG provided significant protection against leprosy, ranging from 20% to 80%. Fine, P., Tubercle, 65:137-153 (1984). An intriguing possibility is that the M. bovis BCG 65kD antigen is involved in engendering the immune protection

-22-

provided by this vaccine against M. leprae, as well as against M. tuberculosis.

In addition to the 65kD antigen, there is evidence that the 19kD and 71kD antigens of M. tuberculosis may be particularly important in the immune response to this bacillus. Helper T cell clones from tuberculosis patients have been isolated which respond to the recombinant 19kD protein. The 71kD antigen is recognized by the humoral immune system of both mice and rabbits, and antibody to this antigen has been shown to be a prominent component of hyperimmune anti-M. tuberculosis rabbit sera.

VIII. Isolation of DNA Clones for Genes Encoding Proteins of Additional Mycobacteria

Using the procedures described above for isolation of genes encoding M. tuberculosis proteins, genes encoding proteins of additional mycobacteria were isolated. DNA clones containing genes encoding the following proteins were isolated:

<u>Mycobacterium</u>	<u>Protein</u>	<u>Clone</u>
<u>M. bovis</u> BCG	71kD	PL1-101
	65kD	PL1-105
	19kD	PL1-501
	14kD	PL1-502
<u>M. smegmatis</u>	65kD	PL1-206
<u>M. avium</u>	65kD	PL1-401
<u>M. africanum</u>	65kD	PL1-301

-23-

For purposes of comparison, genes encoding the following proteins were isolated for M. tuberculosis and M. leprae:

	<u>Mycobacterium</u>	<u>Protein</u>	<u>Clone</u>
05	<u>M. tuberculosis</u>	71kD	Y3272
		65kD	Y3150
		19kD	Y3147
		14kD	Y3248
	<u>M. leprae</u>	65kD	

10 The following strains were used for this purpose:

	<u>Species</u>	<u>Isolate</u>
	<u>M. leprae</u>	Armadillo isolate (WHO)
	<u>M. tuberculosis</u>	Erdmann strain
15	<u>M. africanum</u>	African clinical isolate
	<u>M. bovis</u> BCG	Danish vaccine strain
	<u>M. smegmatis</u>	MC <sup>2</sup> -6
	<u>M. avium</u>	AIDS patient isolate

20 DNA from recombinant lambda gt11 clones was isolated, as described above, and mapped with restriction endonucleases, using standard techniques. Davis, R.W. et al., Advanced Bacterial Genetics: A Manual for Genetic Engineering, Cold Spring Harbor (1980).

25 Figure 4 presents a comparison of the restriction maps for four genes of M. tuberculosis with the restriction maps for four genes of M. bovis BCG which encode proteins of the same molecular weight. As is evident from the figure, in each case, the

-24-

restriction sites on the two genes (e.g., those on the M. tuberculosis gene and those on the M. bovis gene which encodes a protein of the same molecular weight) are essentially identical. This indicates  
05 that the sequence of the genes of the two myco-  
bacteria (at least those encoding these four pro-  
teins) are very similar and, therefore, the proteins  
they encode are also very similar.

Figure 5 presents a comparison of the restric-  
10 tion map for the gene encoding the 65kD protein for  
the six mycobacteria. As is evident, the restric-  
tion maps for the genes encoding the 65kD protein of  
M. tuberculosis, M. africanum, M. bovis BCG, M.  
smegmatis and M. avium are essentially identical.

15 The fact that there is no detectable difference  
among these mycobacteria at the level of the  
restriction map is an indication that, at least at  
this level, the encoded proteins are the same.

As is also evident, the map of the M. leprae  
20 65kD gene has several identical restriction sites in  
common with those of the other mycobacteria; it also  
has two sites not found in the other genes and lacks  
three sites present in the others. This indicates  
25 that, at the level of the restriction map, there are  
similarities in the DNA (and the encoded protein).  
In addition, however, there are differences apparent  
at this level.

#### IX. Diagnostic, Therapeutic and Preventive Applications

30 The isolation of genes encoding major protein  
antigens of M. tuberculosis makes it possible to

-25-

address problems which presently exist in diagnosing  
treating and preventing tuberculosis. Isolation of  
genes encoding proteins of other mycobacteria, such  
as M. bovis BCG, M. africanum, M. smegmatis and M.  
05 avium makes it possible to address similar problems  
in diseases which they cause.

The nucleotide sequence of three of the five  
genes has been determined. The sequence of the  
remaining genes can be determined using well-known  
10 methods, such as that of Sanger et al. Sanger, F.  
et.al., Proceedings of the National Academy of  
Sciences, USA, 74:5463-5467 (1977). The amino acid  
sequence of each of the immunodominant proteins has  
been deduced from the nucleotide sequence of the  
15 three genes and can be done for the others.

Identification and characterization of the  
genes for major tuberculosis protein antigens and of  
the proteins themselves make it possible to develop  
improved reagents for diagnosis and immuno-  
20 prophylaxis of tuberculosis. Proteins antigens  
encoded by an entire gene, or amino acid sequences  
(e.g., peptides, protein fragments) which make up  
the antigenic determinant of a M. tuberculosis  
25 antigen (i.e., M. tuberculosis-specific antigenic  
determinants) may be used in serodiagnostic tests  
and skin tests. Such antigens would be highly  
specific to the tuberculosis bacillus and the tests  
in which they are used would also be highly  
specific. Highly specific serological tests would  
30 be of great value in screening populations for

-26-

individuals producing antibodies to M. tuberculosis-specific antigenic determinants; in monitoring the development of active disease in individuals and in assessing the efficacy of treatment. As a result,  
05 early diagnosis of tuberculosis will be feasible, thus making it possible to institute treatment at an early stage of the disease and, in turn, to reduce the likelihood it will be transmitted.

As a result of the work described, it is also  
10 possible to determine which segment(s) of the M. tuberculosis antigen is recognized by M. tuberculosis-specific T cells. A mixture of peptides recognized by helper T cells can serve as a specific skin test antigen useful in assessing  
15 immunological status (delayed hypersensitivity) of infected individuals and those with whom they come in contact. This specific skin test antigen would be useful in evaluating rapidly the immunological efficacy of anti-tuberculosis vaccines.

20 It is reasonable to expect that the products encoded by M. tuberculosis genes, particularly those shown to be recognized by helper T cells, are themselves immunogenic and thus useful components of vaccines against tuberculosis. These products  
25 include proteins and portions of such proteins (e.g., polypeptides and peptides). For example, one approach to vaccine development is the introduction of genes encoding products (e.g., polypeptides) which provide immunological protection into viruses  
30 such as vaccinia virus, or bacteria, such as cultivatable mycobacteria, thus producing a vaccine

-27-

capable of engendering long-lasting and very specific immunity. The genes encoding five immunodominant protein antigens of the tuberculosis bacillus, described herein, are useful for that  
05 purpose; genes encoding the 65kD, 19kD and 71kD antigens, or a portion thereof, are particularly valuable in vaccine construction.

Because of the similarities in the DNA encoding similarly-sized proteins and, thus, of the encoded 10 proteins themselves, it is possible that, for example, a vaccine effective against two or more of the mycobacteria can be produced.

#### EXEMPLIFICATION

##### Isolation and Analysis of Recombinants Expressing 15 the 65kD M. tuberculosis Antigen

The recombinant DNA library of M. tuberculosis genomic DNA fragments in the lambda gt11 vector was constructed as described above. Recombinant phage lambda RY3143 and lambda RY3146 were used. Young,  
20 R.A. et al., Proceedings of the National Academy of Sciences, USA, 82:2583-2587 (1985). Subclones of the mycobacterial DNA inserts in these recombinant phage were constructed in pUC19 or M13mp9 vectors using standard recombinant DNA techniques. Messing,  
25 J. and J. Viera, Gene, 19:269-276 (1982). Maniatis, T. et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982).

-28-

Monoclonal antibodies specific for the 65kD antigen were obtained from the Immunology of Tuberculosis Scientific Working Group under a grant from the WHO/World Bank/UNDP Special Program for  
05 Vaccine Development. These antibodies included IT-13 (WTB-78), IT-31 (SA2D5H4), and IT-33 (MLIIH9). Coates, A.R.M. et al., Lancet, 2:167-169 (1981). Gillis, T.P. and T.M. Buchanon, Immunology,  
10 37:172-178 (1982). Anti-B-galactosidase antibodies were purchased from CooperBiomedical. Polyclonal rabbit antisera directed against a sonicate of M. tuberculosis strain H37Rv were elicited as described by Minden and co-workers. Minden, P. et al., Infect. Immun., 46:519-525 (1984). Results are  
15 shown in Table 2.

-29-

TABLE 2: PATTERNS OF ANTIBODY REACTIVITIES<sup>a</sup>

	<u>Number of Clones</u>	<u>Reactivity with Antibodies</u>		
		<u>IT-13</u>	<u>IT-31</u>	<u>IT-33</u>
	27	+	+	+
05	1	+	+	+
	2	+	-	+
	3	-	+	+
	1	+	-	-
	2	-	+	-
	10	-	-	+

<sup>a</sup>: Recombinant clones expressing antigens reactive with the 65kD antigen specific monoclonal antibodies IT-13, IT-31, and IT-33 were isolated as described above. For the initial screen, a pool of the three 15 antibodies was used; it contained a 1:1000 dilution of each antibody to screen a total of about  $8 \times 10^5$  recombinant phage from the lambda gt11-M. tuberculosis library. To determine which monoclonal antibody reacted with which of the 38 plaque-20 purified recombinants, about 100 pfu of each recombinant phage were inoculated in small spots on a lawn of Y1090. The phage were allowed to grow and induced to synthesize the foreign proteins as described previously. The filters were then reacted 25 with a 1:1000 dilution of one of the monoclonal hybridoma antibodies as described above.

-30-

The lambda gt11-M. tuberculosis library was screened with the monoclonal antibodies specific for the 65kD antigen and clones reactive with them were isolated essentially as described by Young et al.

- 05 Young, R.A. et al., Proceedings of the National Academy of Sciences, USA, 82:2583-2587 (1985). Briefly, for each 150mm LB plate, 0.6ml of a fresh overnight culture of Y1090 was infected with 1-2  $\times 10^5$  plaque forming units of the library. After  
10 3.5-4 hours of growth at  $42^\circ\text{C}$ , the plaques were overlaid with a dry nitrocellulose filter which had been saturated with 10mM isopropyl-B-D-thiogalactopyranoside (IPTG). The plates were incubated an additional 3.5-4 hours at  $37^\circ\text{C}$  and then removed to  
15 room temperature and the position of the filters marked. The filters were washed briefly in TBST (50 mM Tris-HCl, pH 8, 150mM NaCl, 0.05% Tween 20) and then incubated in TBST + 20% fetal calf serum. After 30 minutes at room temperature, the filters  
20 were transferred to TBST plus antibody. For the initial screen, the antibody mix contained a 1:1000 dilution of IT-13, IT-31, and IT-33. The filters were incubated with the antibody solution overnight at  $4^\circ\text{C}$  with gentle agitation, washed in TBST and  
25 reacted with biotinylated goat anti-mouse immuno-globulin, the Vectastain ABC reagent, and developer as described by the manufacturer (Vector Laboratories). After the color had developed the filters were washed with several changes of water  
30 and air dried. Phage corresponding to positive signals were twice plaque purified. To determine

-31-

which monoclonal antibodies reacted with which of the recombinant phage, about 100 pfu of a purified phage stock were inoculated in a small spot on a lawn of Y1090 bacteria on an LB plate. The phage  
05 were allowed to grow and induced to synthesize the foreign proteins as described above. The filters were then reacted with a 1:1000 dilution of one of the monoclonal antibodies. The subsequent steps were the same as for the initial screen.

10 Western blot assays were carried out as follows: Cells containing phage or plasmids in which the expression of the foreign sequences was under the control of the E. coli lac gene regulatory sequences were induced to synthesize the foreign  
15 proteins by incubating the cells in the presence of 2.5mM IPTG for 2 hours. Crude lysates of cells expressing lambda gt11 recombinants were made as described in Huynh et al. Huynh, T.V. et al., In: DNA Cloning Techniques: A Practical Approach, (D.  
20 Glover, ed.) IRL Press, Oxford, Vol. 1, pp. 49-78 (1985). Crude lysates of cells expressing plasmid encoded proteins were made by harvesting cells from overnight cultures and resuspending the cells in 10 mM Tris pH7.5/10 mM EDTA containing 100 ug  
25 lysozyme/ml. After 10 minutes at room temperature, SDS was added to a final concentration of 0.5%. A protease inhibitor (Trasylol, Boehringer Mannheim) was added to all crude lysates at a final concentration of 0.3%. The crude protein preparations  
30 were electrophoresed on 10% polyacrylamide-SDS Laemmli gels and the separate proteins electrophor-

-32-

etically transferred to nitrocellulose. Laemmli,  
U.K., Nature, 227:680-685 (1970). Towbin, H. et  
al., Proceedings of the National Academy of  
Sciences, USA, 76:4350-4354 (1979). The immobilized  
05 proteins were reacted with a 1:1000 dilution of  
monoclonal antibody IT-13 in TBST overnight at 4°C.  
The nitrocellulose filters were then washed, reacted  
with peroxidase-conjugated goat anti-mouse immuno-  
globulin, and developed as described by Niman and  
10 co-workers. Niman, H.L. et al., Proceedings of the  
National Academy of Sciences, USA, 80:4949-4953  
(1983).

The sequences of 5'-end-labeled restriction  
fragments of the mycobacterial DNA were determined  
15 by a modification of the partial chemical  
degradation technique of Maxam and Gilbert. Brow,  
M.A.D. et al., Mol. Biol. Evol., 2:1-12 (1985).  
Maxam, A.M. and W. Gilbert, Proceedings of the  
National Academy of Sciences, USA, 74:560-564  
20 (1976). For the M13/dideoxy sequencing studies,  
Sau3AI fragments from the mycobacterial DNA inserts  
were subcloned into the BamHI site of M13mp9. Phage  
DNA was isolated from the M13 recombinants and  
subjected to the dideoxy chain termination  
25 sequencing reactions. Biggin, M.D. et al.,  
Proceedings of the National Academy of Sciences,  
USA, 80:3963-3965 (1983). Sanger, F. et al.,  
Journal of Molecular Biology, 143:161-178 (1980).  
The products of the sequencing reactions were  
30 electrophoresed on 6% acrylamide/7M urea/0.5-2.5 x  
TBE gradient sequencing gels. The gels were dried

-33-

under vacuum and exposed to Kodak XRP-1 film. The nucleotide sequences were determined independently for both strands of the mycobacterial DNA.

Computer-aided analyses of the nucleic acid  
05 sequences and deduced protein sequences were performed using the Databases and programs provided by the Nucleic Acid and Protein Identification Resources of the National Institutes of Health as well as the programs of Chou and Fasman and Hopp and Woods. Chou, P.Y. and G.D. Fasman, Adv. Enzym.,  
10 47:45-148 (1978). Hopp, T.P. and K.P. Woods, Proceedings of the National Academy of Sciences, USA, 78:3824-3828 (1981). The nucleotide sequence of the region containing the M. tuberculosis 65KD gene and the deduced amino acid sequence of the two long open reading frames are represented in Figure 8.

B-galactosidase assays were also carried out. Cells were grown in LB broth or LB broth plus 2.5mM  
20 IPTG to an OD<sub>600</sub> of about 0.3. Crude lysates were made and b-galactosidase activity assayed as described by Miller. Miller, J.H., Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1972).

25 Equivalents

Those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, many equivalents to the specific materials and components described herein. Such  
30 equivalents are intended to be encompassed in the scope of the following claims.

-34-

CLAIMS

1. Isolated DNA encoding an immunogenic protein antigen of Mycobacterium tuberculosis.
2. DNA of Claim 1 selected from the group consisting of DNA encoding Mycobacterium tuberculosis protein antigens of molecular weight 71kD, 65kD, 19kD, 14kD and 12kD.
3. Isolated DNA encoding an immunodominant protein antigen of Mycobacterium tuberculosis, the protein antigen having a molecular weight of approximately 65kD and recognized by a monoclonal antibody selected from the group consisting of: IT-31; C1.1; IIH9; IIC8; T2.3; Y1-2; SA2.D7C and IT-13.
4. Isolated DNA encoding an immunodominant protein antigen of Mycobacterium tuberculosis, the protein antigen having a molecular weight of approximately 19kD and recognized by a monoclonal antibody selected from the group consisting of: IT-10; IT-12; IT-16; and IT-19.
5. Isolated DNA encoding an immunodominant protein antigen of Mycobacterium tuberculosis, the protein antigen having a molecular weight of approximately 71kD and recognized by the monoclonal antibody IT-11.

-35-

6. Isolated DNA encoding an antigenic determinant of Mycobacterium tuberculosis protein.
7. DNA of Claim 6 which encodes an antigenic determinant selected from the group consisting of antigenic determinants of Mycobacterium tuberculosis proteins of molecular weight 71kD, 65kD, 19kD, 14kD and 12kD.
8. Isolated DNA encoding an amino acid sequence of an antigenic determinant of Mycobacterium tuberculosis protein, said protein having a molecular weight of approximately 65kD.
9. Isolated Mycobacterium tuberculosis DNA encoding an immunodominant protein antigen having a molecular weight of approximately 65kD, said DNA selected from the group consisting of:
  - a. the DNA insert of clone Y3141;
  - b. the DNA insert of clone Y3143;
  - c. the DNA insert of clone Y3150;
  - d. the DNA insert of clone Y3253; and
  - e. the DNA insert of clone Y3262.
10. A protein antigen encoded by DNA of Claim 9.
11. A protein antigen of Claim 10, wherein the protein antigen is recognized by a monoclonal antibody selected from the group consisting of IT-31; C1.1; IIH9; IIC8; T2.3; Y1-2; SA2.D7C and IT-13.

-36-

12. Isolated DNA having a nucleotide sequence selected from the group consisting of: a) the nucleotide sequence represented in Figure 6, or a portion thereof; b) the nucleotide sequence represented in Figure 7, or a portion thereof; and c) the nucleotide sequence represented in Figure 8, or a portion thereof.
13. A protein or a peptide selected from the group consisting of: a) proteins or peptides encoded by the nucleotide sequence represented in Figure 6, or a portion thereof; b) proteins or peptides encoded by the nucleotide sequence represented in Figure 7, or a portion thereof; and c) proteins or peptides encoded by the nucleotide sequence represented in Figure 8, or a portion thereof.
14. A peptide having the amino acid sequence of an antigenic determinant of Mycobacterium tuberculosis protein, said antigenic determinant being unique to Mycobacterium tuberculosis protein.
15. A peptide encoded by isolated Mycobacterium tuberculosis DNA, said peptide recognized by helper T cells.
16. A peptide encoded by the Mycobacterium tuberculosis DNA insert of clone Y3150 or a portion of said DNA insert.

-37-

17. Isolated DNA encoding a protein of Mycobacterium africanum, the protein having a molecular weight of 65kD.
18. Isolated DNA encoding a protein of Mycobacterium avium, the protein having a molecular weight of 65kD.
19. A vaccine comprising DNA encoding Mycobacterium tuberculosis protein in a recombinant vaccine vector capable of expressing said DNA.
10. 20. A vaccine of Claim 19 in which the recombinant vaccine vector is vaccinia virus or cultivatable mycobacteria.
15. 21. A vaccine of Claim 20 in which the DNA encodes the 65kD Mycobacterium tuberculosis protein recognized by the monoclonal antibody IT-13, or a portion of said protein.
20. 22. A vaccine comprising DNA encoding an antigenic determinant unique to Mycobacterium tuberculosis cultivatable mycobacteria capable of expressing said DNA.
25. 23. A method of detecting antibody against Mycobacterium tuberculosis in a biological fluid, comprising the steps of:
  - a) incubating an immunoadsorbent comprising a solid phase to which is attached

-38-

- immunodeterminant Mycobacterium tuberculosis protein with a sample of the biological fluid to be tested, under conditions which allow the anti-Mycobacterium tuberculosis antibody in the sample to bind to the immunoadsorbent;
- 05           b) separating the immunoadsorbent from the sample; and
- 10           c) determining if antibody is bound to the immunoadsorbent, as an indication of anti-Mycobacterium tuberculosis in the sample.
24. A method of Claim 23 in which the Mycobacterium tuberculosis protein attached to the solid phase has a molecular weight of approximately 65kD.
- 15       25. A method of detecting antibody against Mycobacterium tuberculosis in a biological fluid, comprising the steps of:
- 20           a) incubating an immunoadsorbent comprising a solid phase to which is attached a peptide having the amino acid sequence of an antigenic determinant of Mycobacterium tuberculosis protein with a sample of the biological fluid to be tested, under conditions which allow antibody against Mycobacterium tuberculosis to bind to the immunoadsorbent;
- 25           b) separating the immunoadsorbent; and
- c) determining if antibody is bound to the immunoadsorbent, as an indication of the

-39-

presence of the antibody against Mycobacterium tuberculosis in the sample.

26. A method of Claim 25 in which the peptide has  
the amino acid sequence of an antigenic deter-  
05 minant which is unique to Mycobacterium tuberculosis protein.
27. A kit useful in detecting antibody against  
Mycobacterium tuberculosis in a biological  
10 fluid, comprising a collection of reagents for  
immunoassay of said antibody, said collection  
of reagents a solid phase to which is attached  
immunodeterminant Mycobacterium tuberculosis  
protein or a peptide having the amino acid  
sequence of an antigenic determinant of  
15 Mycobacterium tuberculosis.

1/43

FIGURE 1


1Kb

12K




Y3275

14K



19K



2/43

FIGURE 1 (Cont'd)

1Kb

65 K


XPXSY  
|||  
■■■R ————— L Y3141  
R ————— L Y3143  
L ————— R Y3150  
L ————— R Y3253  
R ————— L Y3262

71 K

K X BK G PB E E  
|||  
■■■Y3268.  
R ————— L  
R ————— L Y3271  
R ————— L Y3272  
R ————— L Y3273

3/43

FIG.2



4/43  
FIG.3






FIGURE 4



6/43

FIGURE 4 (Cont'd)



7/43




FIG. 5

FIGURE 6

F R V N R L G E I A R P G A R I A H Q G  
 S V S I A S V R \* P D Q A R G S R T K A  
 P C Q S P R \* D S P T R R A D R A P R R  
 TTCCGTGTCATCGCCTCGGTGAGATAGCCCACCCAGGGATCGGCACCAAGGC

10 20 30 40 50 60

AAGGCACAGTTAGCGGGAGGCCACTCTATCGGGCTGGTCCGGCGCCTAGCGCGTGGTCCG  
 E T D I A E T L Y G S W A R P D R V L A  
 G H \* D G R H S L G V L R A S R A G; L R  
 R T L R R P S I A R G P A R I A C W P A

8/43

A A Q G Q Q V V Q V M R G V F G H A Q R  
 P R R V S R L C R L C V A F S A M H N A  
 R A G S A G C A G Y A W R F R P C T T R  
 GCGCGCAGGGTCAGCAGGTTGTGCAGGTTATGGCTGGCCATGCCACACGGC

70 80 90 100 110 120

CGGGCGTCCCAGTCGTCCAACACGTCCAATAACGGCACCCAAAAGGGGTACGTGTTGCG  
 G R L T L N H L N H T A N E A M C L A  
 R A P D A P Q A P \* A H R K R G H V V R  
 A C P \* C T T C T I R P T K P W A C R A

FIGURE 6 (CONT'D)

A E A R E I E V H L R R G L G A R G H L  
 R K R G K \* K C I S A G A S V P G A I W  
 G S A G N R S A S P Q G P R C P G P S G  
 GCGGAAGCGGGAAATAGAAGTGCATCTCCGCAAGGGCCTGGTGC  
 130 140 150 160 170 180  
 CGCCTCGCGCCCTTATCTTCACGTAGAGGCCACGGGGCCACGGTAGAC  
 R F R P F Y F H M E A P A E T G P A M Q  
 P L A P F L L A D G C P G R H G P G D P  
 S A R S I S T C R R L P R P A R P W R S 9/43  
  
 E L D L H P V D G V G L P G L G D V D R  
 N S I S T P S M V W V S P V S V M S T V  
 T R S P P R R W C G S P R S R \* C R P S  
 GAACTCGATCTCCACCCCGTCGATGGTGTGGTCTCCCGGTCTCGGTGATGTCGACCGT  
 190 200 210 220 230 240  
 CTTGAGCTAGAGGTGGGCAGCTACCAACACCCAGAGGGCCAGAGCTGGCA  
 F E I E V G D I T H T E G T E T I D V T  
 V R D G G R R H H P D G R D R H H R G D  
 S S R W G T S F P R G P R P S T S R R

FIGURE 6 (CONT'D)

10/43

R	H	D	E	R	N	L	T	G	R	Q	C	L	P	E	A	A	D	V	
G	T	T	S	E	T	S	P	V	D	S	V	C	P	R	P	Q	P	T	C
A	R	R	A	K	P	H	R	S	T	V	S	A	R	G	R	S	R	R	A
CGGCACGAGCCAAACCTCACCGGTGAGACTGCTGGCCAGGGCTTGCCGAGGCCAGCGTGC																			
250	260	270	280	290	290	300													
GCCGTGCTGGCTTGAGTGGCCAGGACGGGCTCGGGCTCGGGCTGCAC																			
P	V	V	L	S	V	E	G	T	S	L	T	Q	G	L	G	C	G	V	H
A	R	R	A	F	G	*	R	D	V	T	D	A	R	P	R	L	R;	R	A
C	S	S	R	F	R	V	P	R	C	H	R	G	S	A	A	S	T	G	
P	P	P	E	T	A	R	Q	H	G	A	V	H	V	A	R	T	A	H	R
P	P	R	P	R	A	N	T	V	P	Y	M	*	P	A	R	R	I	I	A
P	G	D	R	R	A	P	T	R	C	R	T	C	S	P	H	G	A	S	P
CCCCCGGAGACCGGGCCAACACGGTGGCGTACATGTAGCCCCGACGGGCATCATGGC																			
310	320	330	340	350	350	360													
G	R	L	G	R	A	L	V	T	G	Y	M	Y	G	A	R	R	M	M	A.
G	P	S	R	A	G	V	R	H	R	V	H	L	G	C	P	A	D	D	G
G	S	V	A	B	W	C	P	A	T	C	*	V	A	C	*	R	R		

FIGURE 6 (CONT'D)

R A G V D V F L H G V R G E P L R R Q H  
 E P A \* M F S C T A C A V N P S G A S T  
 S R R R C F P A R R A R \* T P P A P A P  
 CGAGCCGGCGTAGATGTTCTGCACGGCGTGGTGAACCCCTCCGGGCCAGCAC  
 370 380 390 400 410 420 430  
 GCTCGCCGCATCTACAAAGGACGTGCCACGGCACTGGGAGGCCGGTGTGCG  
 S G A Y I N E Q V A H A T F G E P A L V  
 L R R L H K G A R R A R H V G G A G A G  
 A P T S T K R C P T R P S G R R W C R

R H L S R V H V G L G G D A E H P T E M  
 A T F P A S T S A W V V T P S T P P K \*  
 P P F P R P R P R P G W \* R R A P H R N D  
 CGCCACCTTCCCGTCCACGTCGGCCTGGGTGACGCCAGCCACCGAAATG  
 430 440 450 460 470 480  
 CGGGTGGAAAGGGGGCCAGGGCAGGGCAGGGGACCCACCTGGGCTCGTGGCTTAC  
 A V K G A D V D A Q T T V G L V G G F H  
 G G K G R G R R G P H R R A G W R F S  
 W R E R T W T P R P P S A S C G V S I I

FIGURE 6 (CONT'D)

I D M A V G V D D R D H G A V G S A V G  
 S T W L W V \* M T A T T G R S A P R W A  
 R H G C G C R \* P R P R G G R L R G G R  
 ATCGACATGGCTGTGGTAGATGACCACGGGGTCCGGCTGGGC  
 490 500 510 520 530 540 12/43  
 TAGCTGTACCGACACCATCTACTGGCGCTGGTCCCCGCCAGGGGCCACCC  
 D V H S H T Y I V A V V P R D A G R H A  
 R C P Q P H L H G R G R P P R S R P P R  
 S M A T P T S S R S W P A T P E A T P A  
 A I Q V Q R G G G H L G G H Q R V D D D  
 R Y K S S A A A A T S V D T N G S M T I  
 D T S P A R R P P R W T P T G R \* R S  
 GCGATACAAGTCAGCGGGCCACCTCGGTGGACACCAACGGGTGATGACGAT  
 550 560 570 580 590 600  
 CGCTATGTTCAAGGTCAAGGCCACCTGTGGTGGCCAGCTACTGCTA  
 R Y L D L A A A V E T S V L P D I V I  
 S V L G A R R G G R H V G V P R H R D  
 I C T W R P P W R P C W R T S S S \*

FIGURE 6 (CONT'D)

Q P S V T L N E A D I G D I E S A D L I  
 S P V S P S T K L I L E I S N P R T \* \*  
 A Q C H P Q R S \* Y W R Y R I R G P D R  
 CAGCCAGTGTCAAC CCTAACGAAAGCTGATATTGGAGATATCGAATCCGGGGACCTGATA  
 610 620 630 640 650 660  
 13/43  
 GTGGGTACAGTGGAGTTGCTCGACTATAACCTCTATAGCTTAGGGCCCTGGACTAT  
 L G T D G E V F S I N S I D F G R V Q Y  
 A W H \* G \* R L Q Y Q L Y R I R P G S L  
 G L T V R L S A S I P S I S D A S R I S  
 D A R H H L V E A L F R G Q L G L P P Q  
 M P G T T W \* R P C F A V S W D C R H R  
 C P A P P G R G P V S R S A G I A A T G  
 GATGCCGGCACACCCTGGTAGAGGGCTGTTTCGGGGTCAGCTGGGATTGCCGCCACAG  
 670 680 690 700 710 720  
 CTACGGGGGGGGACCATCTCCGGGACAAAGGCCAGTCGACCCATAACGGGGTGTGTC  
 I G P V V Q Y L G Q K A T L Q S Q R W L  
 H G A G G P L P G T E R D A P I A V P

FIGURE 6 (CONT'D)

A R C W R T S A R N R P \* S P N G G C A

A G M H R C R R G T V E K R V R V V P  
 L G C T D V G A A P S R N E Y A S L S H  
 W D A P M S A R H R R E T S T R R C P T  
 GCTGGGATGCACCGATGTGGCAGGGCACCGTCCGAGAAACGAGTACGGTGGTGTGCCA  
 730      740      750      760      770      780  
 CGACCCCTACGGCTACAGCCGGCGTGGCAGCTTGCTCATGGCAGCAAACAGGGT  
 S P H V S T P A A G D L F S Y A D N D W  
 Q S A G I D A R C R R S V L V R R Q G V  
 P I C R H R R P V T S F R T R T G C<sup>14</sup>C<sup>43</sup>

H H A T I G S L D H T R G Q R G N E S A  
 T T R P S A A L I T H G D S A A M N P R  
 P R D H R Q P \* S H T G T A R Q \* I R D  
 CACCACGGACCATGGCAGCCTGATCACACGGGGACAGGGCAATGAATCCGCG  
 790      800      810      820      830      840  
 GTGGTGCCTGGTAGCCGTAAGTAGTGTGGCCCTGTGGCCGTTACTTAGGCC  
 V V R G D A A K I V C P S L A A I F G R  
 G R S W R C G Q D C V P V A R C H I R S  
 W A V M P L R S \* V R P C R P L S D A I

FIGURE 6 (CONT'D)

I G V V E I R C V M Q R \* R V E T V C R  
 S A S S K S V V S C N G N E C S P C A A  
 R R R R N P L C H A T V T S V H R V P P  
 ATCGGGCGTCTGAAATCCGGTTGTCATGCAACCGTAACGAGTGTACCCGTGTGCCGC  
 850 860 870 880 890 900 900 15/43  
 TAGCCCCAGCAGCTTAGGCAACACAGTAGCTTGCCATTGCTCACAGTGGCACACGGCG  
 D A D D F D T T D H L P L S H E G H A A  
 R R R R F G N H \* A V T V L T \* R T G G  
 P T T S I R Q T M C R Y R T N V T H R R  
 L D D G S G R F V F H R H Y I A T T T V  
 W M T A V G G L C S I G T T L P L L R C  
 G \* R Q W E V C V P S A L H C H Y Y G A  
 CTGGATGACGGCAGTGGAGGGTTGTTGACTACATTGCCACTACGGTGTG  
 910 920 930 940 950 960  
 GACCTACTGCCGTCAACCCTCCAAACACAAGGTAGCCGTGATGTAACGGTGTGATGCCAC  
 Q I V A T P P K H E M P V V N G S S R H  
 P H R C H S T Q T G D A S C Q W \* \* P A  
 S S P L P L N T N W R C \* M A V V V T C

FIGURE 6 (CONT'D)

16/43

H	A	G	R	C	R	W	R	T	T	L	P	T	R	K	R	E	E	S	A
T	P	V	D	A	V	G	E	P	R	Y	R	P	E	R	E	N	F	P	P
R	R	*	M	P	L	A	N	H	A	T	D	Q	K	E	R	I	F	R	R
CACGCCGGTAGATGCCGTGGCGAACCAACGCTACCGACCAGAAAGAGAGAATTTCGGCC																			
970	980	990	1000	1010	1020														
GTGGCCCATCTAACGGCAAACGGCTTGGCGATGGCTGGTCTCTCTTAAAGGGGG																			
V	G	T	S	A	T	P	S	G	R	*	R	G	S	L	S	F	,K	G	G
R	R	Y	I	G	N	A	F	W	A	V	S	W	F	S	L	I	K	R	R
A	P	L	H	R	Q	R	V	V	S	G	V	L	F	L	S	N	E	A	A

A	P	R	P	R	A	L	L	T	R	I	L	P	K	R	S	S	M	P	M
H	L	D	L	G	P	C	*	R	A	Y	C	R	S	G	P	Q	C	R	W
T	*	T	S	G	P	A	N	A	H	T	A	E	A	V	L	N	A	D	G
GCACCTAGACCTCGGCCCTGCTAACGGCATACTGCCGATGCGGATGCCGATG																			
1030	1040	1050	1060	1070	1080														
CGTGGATCTGGAGCCCCGGACGATTGCCGTATGACGGCTTACGGCTAC																			
C	R	S	R	P	G	Q	*	R	A	Y	Q	R	L	P	G	*	H	R	H

FIGURE 6 (CONT'D)

V \* V E P G A L A C V A S A T R L A S P  
 G L G R A R S V R M S G F R D E I G I S

D R Y D R Q R S T G \* S V D \* R S R \* P  
 T A T T G K G A Q G E A W T D G R G S R  
 P L R Q A K E H R  $\overbrace{V}$  K R G L T V A V A G  
 GACCGCTACGGCACAGGAAAGGTGAAGCGTGGACTGACGGTAGCCG  
 1090 1100 1110 1120 1130 ; 1140  
 CTGGCGATGCTGCCGTTCCTCGTGTCGACCTGCACCTGACTGCCAGCGCATGGC  
 V A V V P L P A C P S A H V S P R P L R  
 G S R C A F S C L T F R P S V T A T A P  
 R \* S L C L L V P H L T S Q R D R Y G S

E P P F W S Q V F P D V Q A T S R L Q E  
 S R H S G R R S F R M F K Q Q V D Y R K  
 A A I L V A G L S G C S S N K S T T G S  
 GAGCCGCATTCTGGTCCGGATGTTCAAGCAACAAAGTCGACTACAGGAA  
 1150 1160 1170 1180 1190 1200  
 CTGGCGGTAAGGACCGGTCCAGAAAGGCCTACAAGTTCGTTGAGCTGTCCTT  
 L R W E P R L D K R I N L C C T S \* L F  
 A A M R T A P R E P H E L L D V V P L  
 G G N Q D C T K G S T \* A V L R S C S A

17/43

FIGURE 6 (CONT'D)

A V R P R P R Q A R R Q A P A P P P G R  
 R \* D H D R G R H D G K P R R R L R A E  
 G E T T A A G T T A S P G A A S G P K  
 GCGGTGAGACCACGACCGGGCAGGCACGGCAAGCCCCGGCCGCTCCGGCCGA  
 1210 1220 1230 1240 1250 1260  
 CGCCACTCTGGTGGCTGGCCGGTCCGTGCCGTTGCCGGGGGGGGGGGGCT  
 R H S W S R P L C S P L G R R R R' A S  
 P S V V V A A P V V A L G P A A E P G F 18/43  
 T L G R G R C A R R C A G A G G G P R L  
  
 R S S S T V R T R T S P A P W C A Q P R  
 G R H R R R \* G P E R H R L R G V H N R G  
 V V I D G K D Q N V T G S V V C T T A A  
 AGGTCTCATGGCTAACGGAGAACGAGAAGGACCTAACGGCTCCGTGGTGTGCACAACGGGG  
 1270 1280 1290 1300 1310 1320  
 TCCAGCAGTAGCTGCCATTCCCTGGTCTTGCAGTGCCGAGGCACACGTGTTGGCGCC  
 P R \* R R Y P G S R \* R S R P T C L R P  
 T T M S P L S W F T V P E T T H V V A A  
 D D D V T L V L V D G A G H H A C G R G

FIGURE 6 (CONT'D)

19/43

P A M S T S R S A G R R P A L P P C S P	
R Q C Q H R D R R G G D R H C R R A H R	
G N V N I A I G G A A T G I A A V L T D	
CCGGCAATGTCACATCGCGATCGGGGGCGACCCGGCATGCCGGTGCCTCACCG	
1330 1340 1350 1360 1370 1380	
GGCCGTTACAGTTGTAGCGGCTAGGCCGCCGGCTGGCCGTAAACGGCGGCACCGAGTGGC	
R C H * C R S R R P P S R C Q R R A * R	
P L T L M A I P P A V P M A A T S V S	
A I D V D R D A P R R G A N G G H E G V	
T A T L R R * S P L G S V T S T A S R W	
R Q P S G G E V R W A R * R Q R R H A G	
G N P P E V K S V G L G N V N G V T L G	
ACGGCAAACCCCTCCGGAGGGTAAGTCCGGTGGCTAACGTCAACGGCGTCACGCTGG	
1390 1400 1410 1420 1430 1440	
TGCCGTTGGGAGGGCTCCACTTCAGGCAACCCGAGCCATTGCAGTTGCCAGTGCCTGCGACC	
R C G E P P S T R Q A R Y R * R R * A P	
P L G G S T F D T P S P L T L P T V S ' P	
A V R R L H L G N P E T V D V A D R Q S	

FIGURE 6 (CONT'D)

20/43

D T R R A P D R V T P R Q P R T A A T T					
I H V G H R T G * R L G N Q G R Q P L Q					
Y T S G T G Q G N A S A T K D G S H Y K					
GATACACGGTGGCACCGGACAGGGTAACGGCAACCCAAAGGCAGGCCACTACA					
1450	1460	1470	1480	1490	1500
CTATGTGCAGCCCCGTGGCCTGTCCTGGGGAGCCGTTGGTCCCTGCCGGTGTGATGT					
I C T P C R V P Y R R P L W P R C G S C					
Y V D P V P C P L A E A V L S P L W * L					
V R R A G S L T V G R C G L V A A V V L					
R S L G P L P G S T W P T R C H R * T S					
D H W D R Y R G R H G Q P D V T G E Q V					
I T G T A T G V D M A N P M S P V N K S					
AGATCACTGGGACCGCTACCGGGTTCGACATGGCCAACCCGATGTCACCCGGTGAACAAAGT					
1510	1520	1530	1540	1550	1560
TCTAGTGACCCCTGGCGATGGCCCCAGGCTTACAGTGGCCACTTGTCA					
S * Q S R * R P R C P W G S T V P S C T					
I V P V A V P T S M A L G I D G T F L D					
D S P G S G P D V H G V R H * R H V L R					

FIGURE 6 (CONT'D)

R S K S R \* P V P N L K R V D A G C E Q  
 V R N R G D L F L T \* S V S M R A V N S  
 F E I E V T C S ] \* P K A C R C G L \* T A  
 CGTTCGAAATCGAGGTGACCTAACCTAAAGCGTGTGGATGCCGCTGTGAAACAG  
 1570 1580 1590 1600 1610 1620  
 GCAAGGCTTAGCTCCACTGGACAAGGATTGGATTTCGCAACAGCTACGCCGACACTTGTC  
 T R F R P S R N R V \* L T D I R A T; F L  
 N S I S T V Q E \* G L A H R H P S H V A 21/43  
 E F D L H G T G L R F R T S A P Q S C R  
 R V G A G Q S G L A R R R F E R L P S V  
 A S E P G S Q A \* R G D D S S G C H P S  
 R R S R A V R P S A A T I R A V A I R Q  
 CGCGTGGAGCCGGCAGTCAGGCCTAGCCGAGCGATTCCGAGCGGTGCCATCCGTC  
 1630 1640 1650 1660 1670 1680  
 GCGCAGGCCTCGGGCCGTCAAGGCTCGGCCAACGGTAGGGCAG  
 A D S G P L \* A \* R P S S E L P Q W G D  
 R R L R A T L G L A A V I R A T A M R \*  
 T P A P C D P R A R R N S R N G D T L

FIGURE 6 (CONT'D)

22/43

K	W	Q	P	H	R	K	L	G	I	S	G	*	A	T	H'	G	D	R	S
S	G	N	R	T	A	N	S	V	Y	P	G	E	L	L	T	V	I	V	P
V	A	T	A	P	Q	T	R	Y	I	R	V	S	Y	S	R	*	S	F	F
AAGTGGCAACCGCACCGCAAACCTCGGTATATCCGGTACTCACGGTGTGAGCTACGGTTGCC																			
1690	1700	1710	1720	1730	1740														
TTCACCGTTGGCGTGTGACCATATAGGCCACTCGATGAGTGCCACTAGCAAGG																			
L	P	L	R	V	A	F	E	T	Y	G	P	S	S	V	T	I	T	G	
T	A	V	A	G	C	V	R	Y	I	R	T	L	*	E	R	H	D	N	R
H	C	G	C	R	L	S	P	I	D	P	H	A	V	*	P	S	R	E	T
V	V	R	L	D	H	S	G	D	D	R	Q	A	E	P	G	A	T	G	L
L	C	A	L	T	T	A	E	T	I	A	R	P	S	P	V	L	P	A	W
C	A	P	*	P	Q	R	R	S	P	G	R	A	R	C	Y	R	L	G	
GTTGTGGCCTTGACCAACGGGAGACGGATGCCAGGGCCAGGGCTACCGGCTTG																			
1750	1760	1770	1780	1790	1800														
CAACACGGGAACCTGGTGGCCTTGCTTAGGGCTCGGGCCACGGATGGCCGAAC																			
N	H	A	K	V	V	A	S	V	I	A	L	G	L	G	T	S	G	A	Q
Q	A	G	Q	G	C	R	L	R	D	G	P	R	A	R	H	*	R	S	P
T	R	R	S	W	L	P	S	S	R	W	A	S	.	G	P	A	V	P	K

FIGURE 6 (CONT'D)

A G P \* R T A A G E P L E N L G L Q R G  
 R D R D V S P R A N R S K T S D C S A A  
 G T V T Y R G R T A R K P R T A A R P  
 GCGGACCGTGTGACGGTATCGCCGGCGAACCCTCGGACTGCAGCGGGC  
 1810 1820 1830 1840 1850 1860  
 CGCCCTGGCACTGCATAGCGGCCGCCGCTTGGCAGCCTGACGTCCGGCCG  
 R S R S T D G R A F R E F V E S Q L A A  
 P V T V Y R P R V A R F G R V A A R G  
 P G H R I A A P S G S S F R P S C R P R G<sup>23/43</sup>  
 R N T R P I V D H L Q H D V R R P G A Q  
 G I P G P L S I T C S T T C V G P V L K  
 E Y P A H C R S P A A R R A S A R C S S  
 CGGAATACCGGCCATTGTCGATCACCTGCAGGACGTTGCGTCCGGCTCAA  
 1870 1880 1890 1900 1910 1920  
 GCCTTATGGGCCGGTAACAGCTAGTGGACGTCGTGCTGCACGGAGTT  
 P I G P G N D I V Q L V V H T P G T S' L  
 S Y G A W Q R D G A A R R A D A R H E L  
 F V R G M T S \* R C C S T R R G P A \* A

FIGURE 6 (CONT'D)

A R R H D R A G T G V H A G V G Q Q V G  
 R V V T I V P G P V C T R A L A S R L V  
 A S S R S C R D R C A R G R W P A G W S  
 GCGCTCGTCACGATCGTGCACGGGGACCGGTGCA  
 1930 1940 1950 1960 1970 1980 24/43  
 CGCGCAGCAGTGTAGCACGGCCACACGGTGC  
 R T T V I T G P G T H V R A N A L L' N T  
 A D D R D H R S R H A R P R Q G A P Q D  
 R R \* S R A P V P T C A P T P W C T P \*  
 H H L V Q P C R I T R D D H R F G G Q V  
 T T W C N R A A S P G M T T G S G G R S  
 P P G A T V P H H P G \* P P V R G A G R  
 CACCACCTGGTGCACCGTGCATCACCCGGATGACC  
 1990 2000 2010 2020 2030 2040  
 GTGGTGGACCACTGGCACGGCGTAGTGGCCCTACTGG  
 V V Q H L R A A D G P I V V P E P P L D  
 G G P A V T G C \* G P H G G T R P A P R  
 W R T C G H R M V R S S W R N P P C T S

FIGURE 6 (CONT'D)

25/43

E	R	P	L	V	I	W	S	G	N	M	S	V	A	D	R	V	N	R	K
S	A	H	W	*	S	G	P	A	T	*	A	S	L	T	A	S	T	A	S
A	P	T	G	D	L	V	R	Q	H	E	R	R	*	P	R	Q	P	Q	A
GAGCCGCCACTGGTGTGATCTGGTCCGGCAACATGAGCGCTCGCTGACCCGTCAACCGCAAG																			
2050	2060	2070	2080	2090	2100	2110	2120	2130	2140	2150	2160								
CTCGGGTTGACCACTAGAACCAGGCCGTTGTA																			
L	A	W	Q	H	D	P	G	A	V	H	A	D	S	V	A	D	V	A	L
A	G	V	P	S	R	T	R	C	C	S	R	R	Q	G	R	*	G	C	A
R	G	S	T	I	Q	D	P	L	M	L	T	A	S	R	T	L	R	L	G
P	R	H	V	H	R	S	A	F	Q	R	P	P	R	V	Q	T	R	Q	Q
R	D	M	S	T	G	P	R	S	S	G	R	P	E	S	R	R	A	S	S
A	T	C	P	P	V	R	V	P	A	A	A	P	S	P	D	A	P	A	A
CCGGACATGTCCACCGGTCCGGTCCAGCCCCGGAGTCAGCAGCCAGCAGCAG																			

FIGURE 6 (CONT'D)

Q Q V L D E T C Y P L G L R C H P A H R  
 S R S S T R R V I R S D A T R L I A  
 A G P R R D V L S A R S P M P P G S S R  
 CAGCAGGTCTCGACGGAGCTGTATCCGCTCGGATGCCACCCGGCTCATCGC  
 2170 2180 2190 2200 2210 2220  
 GTCGTCCAGGAGGCTCTGCACAAATAGGCAGGCCAGGGCTACGGTGGGCCAGAGTAGCG  
 L L D E V L R T I R E T E S A V R S M A  
 A P G R R S T N D A R D G I G G P E D R  
 C T R S S V H \* G S P R R H W G A \* R T<sup>26/43</sup>  
 V C D G L G I V P Y P L R Q F R V T T D  
 C A T A S G S S P I R C V N S V \* P R I S  
 V R R P R D R P L S A A S I P C N H G S  
 GTGTGGACGGCCTCGGGATCGTCCCTATCCGCTGCGTCAATTCCGGTAAACCACGGAT  
 2230 2240 2250 2260 2270 2280  
 CACACGGCTGCCGGAGCCCTAGGCGAGGGATAAGGCCACGTCAGTTAAGGCACATGGTGCCTA  
 H A V A E P D D G I R Q T L E T Y G R I  
 T R R G R S R G R D A A D I G H L W P D  
 H S P R P I T G \* G S R \* N R T V V S R

FIGURE 6 (CONT'D)

27/43

R	R	K	G	S	S	Q	F	M	T	G	I	G	N	E	L	A	H	T	G	
A	A	R	G	V	R	S	S	*	L	A	S	A	T	N	W	R	T	R	V	
P	Q	G	E	F	A	V	H	D	W	H	R	Q	R	T	G	A	H	G	F	
CGCCGCAAGGGGAGTTGCCAGTTCATGACTGGCATCGGCCAACGAACTGGCGCACACGGGT																				
2290	2300	2310	2320	2330	2340															
GGGGCGTTCCCCCTCAAGCGTCAAGTACTGACCGTAGCCGTTGCTTGACCGCGTGTGCCCA																				
A	A	L	P	T	R	L	E	H	S	A	D	A	V	F	Q	R	V	R	T	
G	C	P	S	N	A	T	*	S	Q	C	R	C	R	V	P	A	C	P	N	
R	L	P	L	E	C	N	M	V	P	M	P	L	S	S	A	C	V	P	K	
F	T	G	L	P	R	R	Q	C	G	S	D	V	V	E	H	P	V	E	R	
S	L	A	C	R	A	D	S	A	A	M	W	S	S	I	R	L	S	A		
H	W	W	P	A	A	P	T	V	R	Q	R	C	G	R	A	S	G	*	A	P
TTCACTGGCCTGCCGCCAGTCAGTGCAGGCATGTGGTCGAGCATCCGGTTGAGCGC																				
2350	2360	2370	2380	2390	2400															
AAGTGACCGGACGGCGGGCTGTCAACCGCGCTACACCAAGCTCGTAGGCCAACTCGCG																				
E	S	A	Q	R	A	S	L	A	A	I	H	D	L	M	R	N	L	A		
*	Q	G	A	A	G	V	T	R	C	R	H	P	R	A	D	P	Q	A	G	
V	P	R	G	R	R	C	H	P	L	S	T	T	S	C	G	T	S	R	R	

FIGURE 6 (CONT'D)

R P E L P H L G G V C V R F G H P D R  
 D P S C P T S V E G F A S G S G T R T G  
 T R V A P P R W R G L R Q V R A P G P V  
 CGACCCGAGTTGCCAACCTCGGTGGAGGGTTGGCTCAGGTTGGGCACCCGGACCCG  
 2410 2420 2430 2440 2450 2460  
 GCTGGCTCAACGGGGTGGAGCCACCTCCCCAAACGCAGTCCAAAGCCCAGTGGCCTGGCC  
 S G L Q G V E T S P N A D P E P V R V P  
 V R T A G G R H L P K R \* T R A G P' G T  
 G S N G W R P P P T Q T L N P C G S R Y<sup>28/43</sup>  
 \* L D L A A I Q R \* V D D F A R G L R D  
 S L T S P R S N G R S T T S L A V C A T  
 A \* P R R D P T V G R R L R S R F A R P  
 TAGCTGACCTCGCCGGATCCAACGGTAGGGTGACTCGCTCGGGTTGGCGAC  
 2470 2480 2490 2500 2510 2520  
 ATCGAACTGGAGCGGGCTAGGGTGGCATCCAGCTGCTGAAGCGAGGCCAAACGGCTG  
 L K V E G R D L P L D V V E S A T Q A V  
 A Q G R R S G V T P R R S R E R N A R G  
 S S R A A I W R Y T S S K A R P K R S R

FIGURE 6 (CONT'D)

R R N G A S A R L M M T I P A V V A A T  
 A A T A P A P A \* \* R F R R S S' R R P  
 P Q R R Q R P L D D D S G G R R G D Q  
 CGCCGCAACGGCGCCAGCGCCCCGCTTGATGACGATTCCGGGGTCTCGGGCGACC  
 2530 2540 2550 2560 2570 2580  
 GCGGCCGTTGCCGGGGTCCGGGAACTACTGCTTAAGGCCGCAGCAGCGCCGCTGG  
 A A V A G A G A Q H H R N R D D R R G  
 G C R R W R G S S S E P P R R P S W  
 R L P A L A R K I I V I G A T T A A V L

N A I T V T I P K M I S I C N I V A S T  
 T Q S P \* R F R K \* S A T S W R R R  
 R N H R D D S E N D Q H L Q H R G V D V  
 AACGCAATCACCGGTGACGGATTCCGAAATGATCAGGATCTGCAACATCGTGGCGTCGACG  
 2590 2600 2610 2620 2630 2640  
 TTGGCTTAGTGGCACTGCTAAGGCTTTACTAGTCGTTAGCAGCGTTAGCTGC  
 V C D G H R N R F H D A D A V D H R R R  
 R L \* R S S E S F S \* C R C C R P T S T  
 A I V T V I G F I I L M Q L M T A D V N  
 L P I D R P V T M T S C P F R L G A A S  
 C P S T G R \* R R \* R R A R F G S E R P A  
 A H R Q A G D D V V P V S A R S G Q H  
 TTGCCCCATCGACAGGCCGGTGAACGATGACGTTCTGGCTCGGAGGCCAGC

29/43

FIGURE 7

1 GAA TTC CAA CCG TCG GTG CAG ATC CAG GTC TAT CAG GGG GAG CGT GAG 48  
Glu Phe Gln Pro Ser Val Gln Ile Gln Val Tyr Gln Gly Glu Arg Glu  
  
30/43  
49 ATC GCC GCG CAC AAC AAG T<sup>TG</sup> CTC GGG TCC T<sup>TC</sup> GAG CTG ACC GGC ATC 96  
Ile Ala Ala His Asn Lys Leu Leu Gly Ser Phe Glu Leu Thr Gly Ile  
  
97 CCG CCG GCC CCG CGG GGG ATT CCG CAG ATC GAG GTC ACT TTC GAC ATC 144  
Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile Glu Val Thr Phe Asp Ile  
  
145 GAC GCC AAC GGC ATT GTG CAC GTC ACC GCC AAG GAC AAG GGC ACC GGC 192  
Asp Ala Asn Gly Ile Val His Val Thr Ala Lys Asp Lys Gly Thr Gly

FIGURE 7 (CONT'D)

33 AAG GAG AAC ACG ATC CGA ATC CAG GAA GGC TCG GGC CTG TCC AAG GAA 240  
Lys Glu Asn Thr Ile Arg Ile Glu Gln Gly Ser Gly Leu Ser Lys Glu 31/43

11 GAC ATT GAC CGC ATG ATC AAG GAC GCC GAA GCG CAC GCC GAG GAG GAT 288  
Asp Ile Asp Arg Met Ile Lys Asp Ala Glu Ala His Ala Glu Glu Asp

19 CGC AAG CGT CGC GAG GAG GCC GAT GTT CGT AAT CAA GCC GAG ACA TTG 336  
Arg Lys Arg Arg Glu Glu Ala Asp Val Arg Asn Gln Ala Glu Thr Leu

7 GTC TAC CAG ACG GAG AAG TTC GTC AAA GAA CAG CGT GAG GCC GAG GGT 384  
Val Tyr Gln Thr Glu Lys Phe Val Lys Glu Gln Arg Glu Ala Glu Gly

FIGURE 7 (CONT'D)

385	GGT TCG AAG GTA CCT GAA GAC ACG CTG AAC AUG GTT GAT GCC GCG GTG	432
	Gly Ser Lys Val Pro Glu Asp Thr Leu Asn Lys Val Asp Ala Ala Val	
133	GCC GAA GCG GAA GGC GGC ACT TGG CGG ATC GGA TAT TTC GGC CAT CAA	480
	Ala Glu Ala Glu Gly GLY Thr Trp Arg Ile Gly Tyr Phe Gly His Gln	
181	GTC GGC GAT GGA GAA GCT GGG CCA GGA GTC GCA GGC TCT GGG GCA AGC	528
	Val GLY Asp GLY Glu Ala Gly Pro Gly Val Ala Gly Ser Gly Ala Ser	
29	GAT CTA CGA AGC AGC TCA GGC TGC ACA GGC CAC TGG CGC TGC CCA	576
	Asp Leu Arg Ser Ser Gly Cys Val Thr Gly His Trp Arg Cys Pro	
77	CCC CGG CGG CGA GCC GGG CGG TGC CCA CCC CGG CTC GGC	615
	Pro Arg Arg Arg Ala GLY Arg Cys Pro Pro Arg Leu Gly	

32/43

33/43

FIGURE 8

5' TCGAACGGGGGTGACCCGGTGCCTCTGGCACTCGGATAGGGGAGTGCTAAG  
 3' AGCTTGCTCCCCGACTGGGCCACGGGGTGAAGAACGTCAGGGTATCCGCTCACGGATTC  
 10 20 30 40 50 60  
 AATAACGTTGGCACTTCGGGACCGGTGAGTAGGTCTGGGACGGTGAAGGCCAGGGGGGGC  
 TTATTGCAACCGTGAAGGGTGGCCACTCACCGATCCAGGCTGGCACTCCGGTCCGGGAG  
 70 80 90 100 110 120  
 GTCCGAGGGAGTGGCAGGGACAACTTGAGCCGTCCGGCTGGGACTGGGGCCACTGGGGCCC  
 CAGCGTGGCTCACCGTGGCTCCCTGTTGAACCTGGAGGGAACTGGGACTGGGGCC  
 130 140 150 160 170 180  
 R G C R H P V T P V S P I R R  
 \* AGCGTAAGTAGGGGGTGGGGTCAACCGGGTGAACCCGGTTCATCCCCGATCCCCGGAGGA  
 TGGCATCGCCCCAACGGGAGTGGGCACTGGGGCAACTGGGGAAAGTAGGGCTAGGGCT  
 190 200 210 220 230 240  
 N H F A M A K T I A Y D E E A R R G L E  
 ATCACTTGGCAATGGCCAAAGACAATTGGGTACGGACAAAGAGGGCTGGCT  
 TAGTGAAGGGTACGGGTCTGTTAACGGCATGGCT  
 250 260 270 280 290 300  
 R G L N A L A D A V K V T L G P K G R H  
 GGGCTTGAAACGGCCCTGGGGATGGGTAAAGGTGACATTGGGGCAAGGGGGCAAGG  
 CCCGAACATGGGGTACGGGCAITCCACTGIAACCCGGGTTGGCT  
 310 320 330 340 350 360  
 V V L E K K W G A P T I T H D G V S I A  
 TCGICCTGGAAAGGAAGTGGGTGGGGTCAACGAAACGATGGGTGCTAGGTAGGGT  
 ACCAGGACCTTCTTACCCCCACGGGGTGGCT  
 370 380 390 400 410 420

34/43

FIGURE 8 (CONT'D)

K E I E L E D P Y E K I G A E L V K E V  
 AGGAGATCGAGCTGGAGGATCCGTACCGAGAAGAATGGGGGGGGAGCTGGTCAAAAGAGGTAG  
 TCCCTCTAGCTCGAACCTCCTAGGCATGCTCTCTAGGCCACTGACCAAGTTCTCCATC  
 430 440 450 460 470 480  
  
 A K K T D D V A G D G T T A T V L A Q  
 CCAAGAACCGATGACCTGGCTGGGGCTGACGGCACCCGACGGGGCACCCGTCGGTGGCCAGG  
 GGTCTCTCTGGCTACTGCAGGCCACTGGCGTGGTGCTGCCGGTGGCACGGACCGGGTCC  
 490 500 510 520 530 540  
  
 A L V R E G L R N V A A G C A N P L G L K  
 CGTGGTTCCGAGGGCCCTGGCCAACGTCGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG  
 GCAACCAAGGGCTCCCCGGACGGCTGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG  
 550 560 570 580 590 600  
  
 R G I E K A V E K V T E T L K G A K E  
 GGGCATCGAAAAGGGGGGGAGGGTACCCGAGACCCCTGGCTCAAGGGGGCAAGGGAGG  
 CCCGTAGCTTTGGCACCTCTCCAGTGGCTCTGGGACGGAGTTCGGGGGGGGTCCCTCC  
 610 620 630 640 650 660 670  
  
 V E T K E Q I A A T A I S A G D Q S I  
 TCGAGACCAAGGAGGAGATTGGGGCAACGGGAGGGATTTGGGGTGAACCAAGTCCATCG  
 AGCTCTGGCTTCTGGCTTAACGGGGCTGGCTAAGGGGGCAACTGGGTAGGTAGCC  
 680 690 700 710 720  
  
 G D L I A E A M D K V G N E G V I T V E  
 GTGACCTGATCGCCGGAGGGCAAGGGAGGGGATGGACAAGGGGGGICATCACCGGTGGAGG  
 CACTGGACCTAGGGCTCCGGCTACCTGTCCACCCGGTGGTGGCAGTGGCAGCTCC  
 730 740 750 760 770 780

35/43

## FIGURE 8 (CONT'D)

E S N T F G L Q L E L T E G M R F D K G  
 AGTCCACACCTTTGGGCTCGAGCTCGAGGTACCGAGGGTATGCCGTTGACAAGGGT  
 TCAAGTTGGAAACCCGACGGTGGCTGGACTGGCTCCCATACGCCAAGCTGTTCCCCGA  
 800 810 820 830 840  
 Y I S G Y F V T D P E R Q E A V L E D P  
 ACACTCTGGGCTACTTCGIGACCCGACCCGGAGGGTCAAGGAGGGCCTGGAGGACCCCT  
 TGTAGAGCCCCATGAAGCACTGGCTGGCTCGCACTGGCACCTCCCTGGGGAA  
 850 860 870 880 890 900  
 Y I L V S S K V S T V K D L P L L E  
 ACATCCCTGGCTCAGCTCCAAAGGTTGCCCACACTGTCAAGGATCTGCCTGGCGAGA  
 TGTAGGACGACAGTCGAGGGTCCACAGGTGACAGTTCTAGACAGTGGACTAG  
 910 920 930 940 950 960  
 K V I G A G K P L L I I A E D V E G E A  
 AGCTCAICGGAGCCGGTAAGCCGGCTGGCTGATCATCGCCGAGGGACCGTCGAGGGCGAGGGCG  
 TCCAGTAGCCCTGGCCATTCGGGAACTAGTGGGAACTAGTGGGACTAGTGGGAACT  
 970 980 990 1000 1010 1020  
 L S T L V V N K I R G T F K S V A V K A  
 TGTCACCCCTGGTCGTCACAAAGATACCGGCACCTTCAAGTGGGAACTGGGCTCAAGGCTC  
 ACAGGTGGGACCAAGGAGTTCTAGGGGGCTAGGAACTGGGAACTGGGAACT  
 1030 1040 1050 1060 1070 1080  
 P G F G D R R K A M L Q D M A I L T G G  
 CGGGCTTCGGGACCCGGAAAGGGGATGGCTGGAGGATAAGGGCAITGGGCAITCTCACGGGTGGTC  
 GGCCGAAGCCGCTGGGGGCTGGGGGCTTACGGGTCCTTACGGGTTAACGGTGGGCAACAG  
 1090 1100 1110 1120 1130 1140  
 Q V I S E E V G L T L E H A D L S L L G  
 AGGAGATAGGAAAGAGGTCGGCTGGGCAACGGGACCCCTGTGGCTGGCTAGGCA  
 TCCACTAGTCGCTTCAGCCGGAATGGGCACTGGGCTTGAGGGACGGGACGGATCCGT  
 1150 1160 1170 1180 1190 1200

FIGURE 8 (CONT'D)

K A R K V V T K D E T T I V E G A G D  
 AGGCCGCAAGGTCGGTCAACCAAGGACGAGACCATCGTCAGGGGGGTGACA  
 TCCGGGGTTCCAGCACCGTGGTCTGGCTCTGGTAGCAGCTCCCAGGGCACTGT  
 1210 1220 1230 1240 1250 1260  
  
 T D A I A G R V A Q I R Q E I E N S D S  
 CCGACGCCATCGCCGGACGGAGTGGCCCAGATCGGAGATCGAGAACAGGGACTCCG  
 GGCTGCGGTAGCGGGCTGGCTCACCGGGTCTAGGGGGTCCCTAGCTCTTGTCGGTGA  
 1270 1280 1290 1300 1310 1320  
  
 D Y D R E K L Q E R L A K L A G G V A V  
 ACTACGACCGTGAGAAAGCTGGCAGGGGGCTGGCCAAGCTGGCCGGGTGGTGA  
 TGATGCTGGCACTCTCCGACGTCCCTGGCCACCCGTTGGACCCACAGGGCCACT  
 1330 1340 1350 1360 1370 1380  
  
 I K A G A A T E V E L K E R K H R I E D  
 TCAAGGGGGTGGCCCCACCCGAGGGTCTGAACCTCAAGGAGGCACCCCATCGAGGATG  
 AGTTCCGGCAAGGGGGTGGCTCCAGCTTGAGTTCTCGGGTTCTGGCTAGCTCCCTAC  
 1390 1400 1410 1420 1430 1440  
  
 A V R N A K A A V E E G I V A G G V T  
 CGGTTCGGCAATTGGCTGGGGCATCGTCGGGGTGGGGTGTGACCC  
 GCCAAGGGTTACGGTTCCGGCAAGCTCTCCGTAGCAAGGGCACCCCCACACTGGC  
 1450 1460 1470 1480 1490 1500  
  
 L L Q A A P T L D E L K Q I F N S G  
 TGTTGCAAGGGGGGACCCCTGGACGGAGCTGAAGGGGACGGGACCCGGG  
 ACAACGTTGGGGCTGGGACCTGGCTGACTTGGCTGAGCTGGCTCCGGGG  
 1510 1520 1530 1540 1550 1560  
  
 A N I V K V A L E A P L K Q I A F N S G  
 CCAACATGGTGAAGGGGGCTGGAGGGGGCTGAAGGGAGATCGGCTTAACCTCCGGG  
 GGTGTAGGCACTTCCACCCGGGACCTGGCTAGGGAAAGTTGAGGG  
 1570 1580 1590 1600 1610 1620

36/43

37/43

FIGURE 8 (CONT'D)

L E P G V V A E K V R N L P A G H G L N  
 TGGAGCCGGCGGGTGGGAGAAGGTGGCAACCTGCCGGCTGCCAGGGACTGAACG  
 ACCCTGGGGACCCACGGCTCTTCACGGGTGGACCCCCGACCCGGCTGACTTGC  
 1830 1840 1850 1860 1870 1880

A Q T G V Y E D L L A A G V A D P V K V  
 CTCAGACCGGGTGTCTACGGAGATCTGGCTCGCTGGCTGGCTGACCCGGTCAAGGGTGA  
 GAGTCTGGCCACAGATGGCTCCTAGACAGAACGGGAGCCACGGACTGGGGCAGITCCACT  
 1690 1700 1710 1720 1730 1740

T R S A L Q N A A S I A G L F L T T E A  
 CCCGTTGGGGCTGGCAGAAATGGGGGTCCATGGGGGCTGTTCCCTGACCCGGAGGGCG  
 GGGCAAGGGGGGACGGTCTTACGGGGCAAGGTAGGGGGGACAAAGGAUTGGGGCTCCGG  
 1750 1760 1770 1780 1790 1800

V V A D K P E K E K A S V P G G D M G  
 TCGTTGCCGACAAGCCGGAAAAGGGAAAGGGCTTCCCCTGGCTGGGGGACATGGGTG  
 AGAAACGGGCTGTTGGCCTTTTCCTCTTCCGAAGGGAAAGGGCACCCGGCTGTACCCAC  
 1810 1820 1830 1840 1850 1860

G M D F \*  
 GCATGGATTCTGACCCCCGGAGAAGTCCGAGGGAGGGGGGCTTGCGGGGGGG  
 CCTACCTAAAGACTGGGGGGCTCTCAGGGCTCCGGGGCACGGGA AACACCCCC  
 1870 1880 1890 1900 1910 1920

GGGCTCCCTCTGGGAGCTACGGTACCCGAGAACCCACGGAGA  
 CCCGAGGAGACCAACCCCTGGCATGGCTCTGGCTGGGTCAACATCCGGTGGAA  
 1930 1940 1950 1960 1970 1980

TGGCCGGCTGTGGGGGGAGTGGGGGGCTCTGGGTGCAGCACATGGGTACGA  
 ACCGGGACACCCCCGCTCAGCCCCGGAGAGCCACGGTGGGGCTACCCATGGCT  
 1990 2000 2010 2020 2030 2040

FIGURE 8 (CONT'D)

FIGURE 8 (CONT'D)

FIGURE 8 (CONT'D)

2960      2980      2970      2980      2990      3000  
 GCTCCCCGATGCCCTGTTAGGGAGCCGAATTCCCGATGCCGATGTTCCCGCTGCCGA  
 CCAGGGCTACGGGACAAAGTCCCTCGGGCTTAAGGGCTACGGCTACAAAGGGACGGCCT  
 T G I S H L S G S H S G I G I H G S G S  
  
 3010      3020      3030      3040      3050      3060      40/43  
 GTTGAATAAGCCGACGGTGCCCGAGTTCCCGAAGGCCGATGTTGCCCGCTACCCGA  
 CAACTTATTCGGCTGCACGGCCACGGGCTCAAGGGCTTCGGCTACAAACGGGATGGCT  
 N F L G V H G T G S H N G F G I H G S G S  
  
 3070      3080      3090      3100      3110      3120  
 GTTGAAGCCGGAAACCCATCTGGTGATCACCGGTGATCCCGAACCCGATATTCCCGCT  
 CAACTTCGGCGGCTTGGGTAGACCACTAGGGCCACTAGGGCTTGGCTATAAGGGCCGA  
 N F G G F G M Q H D G T 1 G F G I H G S  
  
 3130      3140      3150      3160      3170      3180  
 ACCGGTGTGGCCGAAGCCGATATTCCCGTGGCCGAGGTGGCTGCCGAGGGCTGCCGCT  
 TGGCCACACAACGGCTTCGGCTATAAGGGCAGGGCTCAACGGGCTCCGGCTAACGGGA  
 G T H G F G I N G D G L H G L G L N G S  
  
 3190      3200      3210      3220      3230      3240  
 GCCGGTGTGGCGCTGGCGATGTTGGGGTGTGGCCGATGGTGTGGTGTGTTGTTGTT  
 CGGCCACACAACGGGACGGCTACAACGGCCACGGGACAACGGGCTACAACAAACAA  
 G T H G S G I H G T G T H G S G I H N H H  
  
 3260      3260      3270      3280      3290      3300  
 GCCGATGTTGTTGTTGGCGATGTTGGCGATGTTGCCGCTGCCGGTGTGGCTGCCGA  
 CGGCTACACAACAAACGGCTACAACGGCTACAACGGGCTACAAACGGGACGGCT  
 G I H N H G I H N G I H G S G T H N G F  
  
 3310      3320      3330      3340      3350      3360  
 GCCCAGATGATCTGGCCGATGTCGATGCCGAGGTCTGGCAAGAACCTGGCCT  
 CGGGTCTAACTAGACCCGGCAAGAACGGCTACAGCTACGGCTCCAAAGGGCT  
 G L H I Q G N K G I D I G L H R L V Q . Q

## FIGURE 8 (CONT'D)

				41/43
3370	3380	3390	3400	3420
CCAGGGCCAGTTGTGCCAGGGCAGACGGCATCGAAGTGGTAACCAGCCATCGGCC	GGTCCCCGGCTAACACGCTTGGTAGCTTCAACCATTGGCTGGTAGGGCG	W P A L Q A V A S A D F H Y G A M A A		
3430	3440	3450	3460	3480
CACGTCCAATGCCAACATTGGCTGGTATGCCGGCTGGACGTCCATGAGGGGGAGGGT	GTCAGGGTTACGGGTAAACGAGCATACGGGGAGCTGCAAGGTACTCGGC	V D L A W H Q E Y A A E V D H L A P A H		
3490	3500	3510	3520	3540
CTGGCCAAACCAAGTCCGTAGCTGCCAGCACGCTGGCATCGAGCCACGATTGGCC	GACGGGTTGGTCAAGGATCGGACGGTCTGGTAGTCCGGTGCTAACCGG	Q G F W H T A L Q M L G R H A V V		
3550	3560	3570	3580	3600
TGCCGGCTGGCACGGGTGGCCAGGCCCTCGAACGGGCTCGCTGCGCATGGCCTG	ACGGGGCTGGCACGGTGGCACCGGGGGGGGAGCTGGGAGCTGGGAC	A P Q V T A A L A E F A T A M A Q		
3610	3620	3630	3640	3660
TGGGGCCCTTGTGGCTGGCTGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	ACGGGGGAACAAGGGGGAAAGGGGACGGGGGGGGGGGGGGGGGG	A A Q E A Q A A T S L W A L Y Q T A		
3670	3680	3690	3700	3720
GACGGCCCATCATGGCCGGGGACGGGACGGGGGGGGGGGGGGGGGGGGGG	CTGGGGGTAGGGTAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	V A M W A A S P G L W A G S T L E S T		
3730	3740	3750	3760	3780
GACGGAGCCAAAGGGACGGTATTGGACGGGAGCAATTCTTICGGCCAGG	CTGGCTGGGTTCGGTGGATAACTGGCTCGTTAAGAAGGGGGGGGG	V S A I S A L E E A L E G W A T		

FIGURE 8 (CONT'D)

3790      3800      3810      3820      3830      3840  
 GCCCGAACATTAGCCGICCCCCGACCCGGC  
 CCGGGTCTTAATGCCAGGGCTGGCCCGTTGAG  
 A A I L P G S G F M L A S H I E      42/43  
 3850      3860      3870      3880      3890      3900  
 TGGCCGAAACCACCCAAAAATGGGGCTTGTCAAGCCGATCCAACTTAAC  
 ACCGGCGTTGGTTTACGGCCGAACAGTCGGCTAGGTTGAATTGACAGTGG  
 P P L W A F H P S T L R D L K V T L S R  
 3910      3920      3930      3940      3950      3960  
 TTGGCCGCGGTATCGGCACCTCAATTCAACTCATCTTGGGTCAITCTT  
 AACGGCACGGCATAGCCGTGAAGTTATGGTGAGTAGA  
 Q R P P I P V E I G S H K P T M K P A G      4000  
 3970      3980      3990      4000      4010      4020  
 CCTAGGGAAACGCCAGCTTACCTAGTCCCCTAGGTAGGGACTGGCGGACT  
 GGATCCCTTGGGGTCAAATGGATCAGGGCCCATCCCCGGCTGACCGGG  
 R P V A L K G L G P Y P V P R S A A  
 4030      4040      4050      4060      4070      4080  
 TGAGGGGCTGCCACCTGGCCCGTAATGTCGGCTGGTATGGCAAGG  
 ACTCCCAAGACGGTGGGACCCATTACAGGGACCATACCCGGCTGG  
 S P R G G A G Y H R Q P L C R R P G  
 4090      4100      4110      4120      4130      4140  
 AAGAGTTCGCTCCGGGACGGGTTCACCCGGTTGATCGAACATGT  
 TTCTCAACGAGGGCTGGCAAGTGGCCAACTAGCTTGTACAGCT  
 L T A G R R T \*  
 4150      4160      4170      4180      4190      4200  
 GCCTCACCGAACCAACTGGCTGGCTACCCGGCCACGGATTGG  
 CGGAGTGGCTGGTTGAGGGACGAAGGGCTGGGTTGGCTGC

FIGURE 8 (CONT'D)

43/43